
Drug Discovery and Evaluation
Pharmacological Assays

Springer

Berlin

Heidelberg

New York

Barcelona

Hong Kong

London

Milan

Paris

Tokyo

H. Gerhard Vogel (Ed.)

Drug Discovery and Evaluation

Pharmacological Assays

Second Completely Revised, Updated, and Enlarged Edition

Including a CD-ROM



Springer

Editor

Prof. Dr. med. Dr. s.c. H. Gerhard Vogel

Johann Wolfgang Goethe Universität
Frankfurt am Main
Germany

ISBN 3-540-42396-6 Springer-Verlag Berlin Heidelberg New York

Library of Congress Cataloging-in-Publication Data

Drug discovery and evaluation : pharmacological assays / H. Gerhard Vogel ...
(ed.).-- 2nd ed.

p. ; cm.

Includes bibliographical references.

ISBN 3540423966 (alk. paper)

1. Pharmacology, Experimental. 2. Drugs--Design. 3. Drugs--Testing. I. Vogel, H. Gerhard, 1927-

[DNLM: 1. Drug Design--Laboratory Manuals. 2. Drug Evaluation--methods--Laboratory Manuals. 3. Drug Evaluation, Preclinical--methods--Laboratory Manuals. QV 744 D79335 2002]
RM301.25 .V64 2002
615'.7--dc21

2002019340

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

Springer-Verlag Berlin Heidelberg New York
a member of the BertelsmannSpringer Science+Business Media GmbH

<http://www.springer.de>

© Springer-Verlag Berlin Heidelberg 2002
Printed in Germany

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publisher cannot guarantee the accuracy of any information about dosage and application thereof contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Cover Design: *design & production*, Heidelberg
Dataconversion: Büro Stasch, Bayreuth

SPIN: 10841880 14/3130/ag – 5 4 3 2 1 0 – Printed on acid-free paper

Preface to the second edition

The first edition of “Drug Discovery and Evaluation – Pharmacological Assays” has been well accepted by a broad readership ranging from experienced pharmacologists to students of pharmacology. Therefore, already after a short period of time the question for a second edition arose.

The first edition was mainly centered around the personal laboratory experience of the editors and the contributors. The second edition tries to close evident gaps.

The input of biochemistry to pharmacology has grown. Molecular pharmacology puts more emphasis on the mode of action of drugs, albeit it becomes clear that the activities of most drugs are not confined to one single mode of action. Studies in single cells become more and more popular, however, they do not cover the complexity of a whole organism. Possible side effects of drugs can be better detected in whole animals than in single cells. Therefore, the new requirements of the health authorities on safety pharmacology put emphasis on experiments not only in whole anesthetized animals but in conscious ones. The second edition of this book takes note of these requirements and devotes special chapters for each indication to safety pharmacology.

Molecular biology also introduced new methods to pharmacology, such as the polymerase chain reaction (PCR), reverse PCR, Northern, Western and Southern blotting. Very recently, microarray technology, proteomics, and mass spectroscopy were added as novel *in vitro* methods. Furthermore, genetically modified animals have been created which resemble human diseases. Pharmacogenomics has already begun to influence pharmacology and even will have greater input in the future. Special attention is given to these new achievements in various chapters of the book.

The editor and the co-editors are well aware that the rapid progress in biology during the next decades will change the methodological approach. Electronic media will help the researcher for continuous information. However, it becomes more and more evident, that young pharmacologists have only insufficient training in the classical pharmacological methodology. Searching for these methods, e.g., for safety pharmacology, the researchers cannot find sufficient information on the methodological details in the electronic data bases currently available. This book covering the pharmacological methods of more than hundred years may be of help.

The guidelines concerning the care and use of laboratory animals have been updated.

A change in paradigm of pharmacological research has been claimed but superiorities of these new approaches compared to the old ones have still to be proven. To address this, an introductory chapter on new strategies in drug discovery and evaluation has been added, including combinatorial chemistry; high throughput screening, ultra high throughput screening and high content screening; pharmacogenomics, proteomics and array technology. Some critical thoughts on errors in screening procedures have been added.

At this place, we would like to express our sincere thanks to all colleagues who contributed to the new and to the first edition of this book. Their names and their positions are given alphabetically.

March 2002

H. Gerhard Vogel
Also in the name of the co-editors

Preface to the first edition

This book is intended to be an aid for experienced pharmacologists as well as for newcomers in the field of experimental pharmacology. The student in pharmacology, the pharmacist and the medicinal chemist will find a survey of pharmacological assays that can be used for a given indication and for which methods have demonstrated their relevance. The researchers working in special fields of pharmacology will find assays in other, unfamiliar areas which might help to expand their own research.

Certain therapeutic domains, such as cardiovascular, respiratory and renal disorders, psychiatry and neurology, peripheral nerve function, pain and rheumatic diseases, metabolic and endocrine diseases including diseases of the gastrointestinal tract, are discussed in this book.

Each chapter is divided into pharmacological classes, e.g., anxiolytics, anti-epileptics, neuroleptics, antidepressants, or anti-Parkinson drugs. For each class, in vitro methods, tests on isolated organs and in vivo methods are described.

For each method the purpose and rationale are given first, followed by a description of the procedure, evaluation of the data, modifications of the method described in the literature, and the relevant references. If possible, a critical assessment of the method based on personal experience is added. The hints for modifications of the method and the extended reference list will be of value for the experienced pharmacologist.

A few words for the justification for a book of this kind:

In 1959, A. J. Lehman, Director of the Division of Pharmacology at the Food and Drug Administration, USA, wrote:

... Pharmacologists are individualists. Like most scientists they are seldom willing to copy each other's techniques in detail, and so their methods vary from one to the other. Nevertheless, there are basic principles and techniques which must be applied to establish the safety of a new drug.

Visitors could also read a sticker in his office:

You too can learn pharmacology, in only three lessons: each of them lasting ten years.

Pharmacologists have always used methods from neighboring disciplines; in the past, e.g. from anatomy, pathology, surgery, zoology and predominantly physiology. Useful methods also came from electrophysiology and the behavioral sciences. Earlier drug discovery was almost exclusively based on animal experiments, clinical observations and serendipity.

In recent years, a major input has come from biochemistry. The effect of many drugs in human therapy could be explained biochemically as effects on specific enzymes or receptors. With the detection of more and more receptor subtypes, the activity spectrum of a single compound became more and more complicated. At present, molecular biology provides pharmacologists with human receptors and ion channels expressed in mammalian cells in culture. This avoids the apparently existing species differences, but the multitude of natural and perhaps artificial subtypes raises the question of physiological and pathological relevance.

The challenge for the pharmacologist always will be to correlate *in vitro* data with *in vivo* findings, bearing in mind the old saying: “*In vitro simplicitas, in vivo veritas*”. The effects found in tissue cultures are quite often not typical for an intact organism.

Pharmacologists, especially in industry, have the task to find new drugs for human therapy by using appropriate models. Pharmacological models have to be relevant, that means they should predict the intended therapeutic indications. A pharmacological model can be considered relevant or correlational, if the effects obtained correlate with results observed in human therapy.

To be relevant or “correlational”, a model has to fulfill some basic criteria:

- First, the model must be sensitive in a dose-dependent fashion to standard compounds that are known to possess the desired therapeutic property.
- Second, the relative potency of known active agents in the model should be comparable to their relative potency in clinical use.
- Third, the model should be selective, i.e. the effects of known agents in this therapeutic indication should be distinguishable from effects of drugs for other indications. Positive data with a new compound allow the prediction of a therapeutic effect in patients.

If new assays are applied to indications for which no effective drug is known, there must be sufficient evidence that this model is relevant for the pathological status in this indication.

The methods presented in this book have been selected according to these criteria.

Considerable discussion is going on about the necessity of animal experiments. One has to accept that only the whole animal can reflect the complexity of a human being. Even an experiment with human volunteers is only a model, albeit a highly relevant one, to investigate therapeutic effects in patients. The degree of relevance increases from isolated molecules (e.g. receptors or enzymes) to organelles, to organs up to conscious animals and human volunteers.

Without any doubt, animal experiments are necessary for the discovery and evaluation of drugs. However, they should be performed only if they are necessary and well conceived.

In Chapter N, regulations existing in various countries concerning the care and use of laboratory animals are listed. Furthermore, guidelines for anesthesia, blood collection and euthanasia in laboratory animals are given. In carrying out animal experiments, one must adhere strictly to these guidelines. Following these rules and planing the experiments well, will eliminate or minimize pain and discomfort to the animal. The methods described in this book had the welfare of the animals as well as the benefit of the procedure for the well-being of mankind in mind.

Here, we would like to express our sincere thanks to all colleagues who contributed to this book. Their names and positions are given alphabetically below.

Autumn 1996

H. Gerhard Vogel
Wolfgang H. Vogel

Editor and co-editors

Editor

Prof. Dr. Dr. H. Gerhard Vogel Johann Wolfgang Goethe-Universität, Frankfurt

Coeditors

Prof. Dr. Wolfgang H. Vogel Jefferson Medical College, Thomas Jefferson University, Department of Pharmacology, Philadelphia, USA

Prof. Dr. Bernward A. Schölkens Johann Wolfgang Goethe-Universität Frankfurt, Aventis Deutschland GmbH

Prof. Dr. Jürgen Sandow Johann Wolfgang Goethe-Universität Frankfurt, Aventis Deutschland GmbH

PD Dr. Günter Müller Ludwig Maximilian-Universität München, Institut für Genetik, Aventis Deutschland GmbH

Dr. Wolfgang F. Vogel Assistant Professor, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Canada

Contributors

List of contributors to the second edition

<i>Albus, Udo</i>	Aventis Pharma Research, D-65926 Frankfurt
<i>Bickel, Martin</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Bleich, Markus</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Dere, Ekrem</i>	Institute of Physiological Psychology, Heinrich Heine-Universität Düsseldorf
<i>Gögelein, Heinz</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Herling, Andreas W.</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Hropot, Max</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Laux, Volker</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Just, Melitta</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt
<i>Müller, Günter</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Rieß, Günther</i>	Aventis Pharma Research, D-65926 Frankfurt
<i>Sadow, Jürgen</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Schäfer, Hans-Ludwig</i>	Aventis Pharma Research, Metabolism Research, D-65926 Frankfurt
<i>Vogel, Wolfgang F.</i>	Assistant Professor, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Canada
<i>Vogel, Wolfgang H.</i>	Jefferson Medical College, Thomas Jefferson University, Department of Pharmacology, Philadelphia, USA
<i>Wirth, Klaus J.</i>	Aventis Pharma Research, Cardiovascular Research, D-65926 Frankfurt

List of contributors to the first edition

<i>Albus, Udo</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Bartlett, Robert R.</i>	Hoechst-Marion-Roussel, Immunopharmacology, D-65174 Wiesbaden
<i>Bickel, Martin</i>	Hoechst-Marion-Roussel, Metabolism Research, D-65926 Frankfurt
<i>Brioni, Jörge D.</i>	Abbott Laboratories, Neuroscience Research, Abbott Park, IL 60064 USA
<i>Gögelein, Heinz</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Greger, R.</i>	Institute of Physiology, University of Freiburg, D-79104 Freiburg
<i>Herling, Andreas W.</i>	Hoechst-Marion-Roussel, Metabolism Research, D-65926 Frankfurt
<i>Hock, Franz Jakob</i>	Hoechst-Marion-Roussel, General Pharmacology, D-65926 Frankfurt
<i>Hropot, Max</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Huger, Francis P.</i>	Hoechst-Marion-Roussel, Neuroscience Research, Sommerville, NJ, USA
<i>Jablonka, Bernd</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Just, Melitta</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Linz, Wolfgang</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Maas, Jochen</i>	Hoechst-Marion-Roussel, Preclinical Development, D-65926 Frankfurt
<i>McGaugh, James L.</i>	University of California at Irvine, Irvine, Ca 92717, USA
<i>Müller, Günter</i>	Hoechst-Marion-Roussel, Metabolism Research, D-65926 Frankfurt
<i>Raiss, Ruth X.</i>	Hoechst-Marion-Roussel, Osteoarthritis Research, D-65174 Wiesbaden
<i>v. Rechenberg, Wolfrad</i>	Hoechst-Marion-Roussel, Metabolism Research, D-65926 Frankfurt
<i>Rudolphi, Karl A.</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Schölkens, Bernward A.</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt
<i>Seeger, Karl</i>	Hoechst-Marion-Roussel, Pharma Research, D-65926 Frankfurt
<i>Weithmann, K. U.</i>	Hoechst-Marion-Roussel, Immunopharmacology, D-65174 Wiesbaden
<i>Wirth, Klaus J.</i>	Hoechst-Marion-Roussel, Cardiovascular Research, D-65926 Frankfurt

Contents

Introduction	
Strategies in drug discovery and evaluation	1
0.1	Historical approaches in drug discovery 1
0.2	Pharmacological approaches of modern medicine 2
0.3	New approaches in drug discovery 3
0.3.1	Combinatorial chemistry 6
0.3.2	High throughput screening, ultra high throughput screening, and high content screening 7
0.3.3	Technologies for high throughput screening 8
0.3.4	Pharmacogenomics 14
0.3.5	Proteomics 18
0.3.6	Array technology 19
0.4	Errors in screening procedures 20
 Chapter A	
Cardiovascular activity	23
A.1	Cardiovascular analysis 26
A.1.1	<i>In vitro</i> methods 26
A.1.1.1	α_1 -adrenoreceptor binding 26
A.1.1.2	α_2 -adrenoreceptor binding 29
A.1.1.3	Electrically stimulated release of [^3H]norepinephrine from brain slices 31
A.1.1.4	Imidazoline receptor binding 33
A.1.1.5	β -adrenoreceptor binding 36
A.1.1.6	β_1 -adrenoreceptor binding 38
A.1.1.7	β_2 -adrenoreceptor binding 39
A.1.1.8	Adenosine A_1 receptor binding 40
A.1.1.9	Adenosine A_2 receptor binding 43
A.1.1.10	Adenosine A_3 receptor binding 44
A.1.1.11	Inhibition of adenosine uptake in human erythrocytes 45
A.1.1.12	Inhibition of the angiotensin-converting enzyme <i>in vitro</i> 46
A.1.1.13	Quantitative autoradiographic localization of angiotensin-converting enzyme 48
A.1.1.14	Angiotensin antagonism 49
A.1.1.14.1	Angiotensin II receptor binding 49
A.1.1.14.2	Angiotensin II induced contraction in isolated rabbit aorta 52
A.1.1.14.3	Angiotensin II antagonism <i>in vivo</i> 53
A.1.1.15	Renin-inhibitory activity using human kidney renin and a synthetic substrate 55

A.1.1.16	PAF binding assay	57
A.1.1.17	Endothelin	58
A.1.1.17.1	General considerations	58
A.1.1.17.2	Evaluation of endothelin activity	59
A.1.1.17.3	Endothelin receptor antagonism <i>in vitro</i>	60
A.1.1.17.4	Endothelin receptor antagonism <i>in vivo</i>	61
A.1.1.17.5	Quantitative autoradiographic localization of endothelin-1 receptor ..	63
A.1.1.17.6	Inhibition of endothelin converting enzyme	63
A.1.1.18	Nitric oxide	66
A.1.1.18.1	General considerations on nitric oxide	66
A.1.1.18.2	Bioassay of EDRF release	67
A.1.1.18.3	Isolated arteries with and without endothelium	68
A.1.1.18.4	Nitric oxide formation by cultured endothelial cells	69
A.1.1.18.5	Expression of nitric oxide synthase	72
A.1.1.19	Inhibition of Na ⁺ /H ⁺ exchange	73
A.1.1.19.1	Inhibition of Na ⁺ /H ⁺ exchange in thrombocytes	75
A.1.1.19.2	Inhibition of Na ⁺ /H ⁺ exchange in cholesterol activated rabbit erythrocytes	75
A.1.1.19.3	Sodium influx into cultured cardiac myocytes	76
A.1.1.19.4	Inhibition of Na ⁺ /H ⁺ exchange into cultured aortic endothelial cells ..	76
A.1.1.19.5	NHE activity measured by intracellular pH in isolated ventricular myocytes	77
A.1.1.19.6	NHE subtype specificity	78
A.1.1.20	Inhibition of phosphodiesterase	79
A.1.1.21	Stimulation of heart membrane adenylate cyclase	80
A.1.1.22	³ H-Forskolin binding assay	81
A.1.1.23	Patch clamp technique	83
A.1.1.23.1	Patch clamp technique in isolated cardiac myocytes	84
A.1.1.23.2	Voltage clamp studies on sodium channels	85
A.1.1.23.3	Voltage clamp studies on potassium channels	87
A.1.1.23.4	Voltage clamp studies on calcium channels	89
A.1.1.23.5	Patch clamp studies on chloride channels	92
A.1.1.24	Measurement of cytosolic calcium with fluorescent indicators	92
A.1.1.25	Measurement of contractile force of isolated cardiac myocytes	93
A.1.1.26	Adrenomedullin	94
A.1.1.26.1	General considerations	94
A.1.1.26.2	Receptor binding of adrenomedullin	96
A.1.1.27	Atrial natriuretic factor (ANF)	97
A.1.1.27.1	General considerations	97
A.1.1.27.2	Bioassay for ANF	98
A.1.1.27.3	Receptor binding of ANF	99
A.1.1.27.4	ANF gene expression	100
A.1.1.27.5	Radioimmunoassay for ANF	102
A.1.2	Studies in isolated organs	102
A.1.2.1	α-Sympatholytic activity in isolated vascular smooth muscle	102
A.1.2.2	α-Sympatholytic activity in the isolated guinea pig seminal vesicle ..	103
A.1.2.3	α-Sympatholytic activity in the isolated vas deferens of the rat	104
A.1.2.4	α-Sympatholytic activity in the isolated rat spleen	106
A.1.2.5	α-Sympatholytic activity in the isolated rat anococcygeus muscle ...	106
A.1.2.6	β ₁ -Sympatholytic activity in isolated guinea pig atria	108
A.1.2.7	β ₂ -Sympatholytic activity in the isolated tracheal chain	109
A.1.2.8	Angiotensin converting enzyme inhibition in the isolated guinea pig ileum	110
A.1.2.9	Contractile and relaxing activity on isolated blood vessels including effects of potassium channel openers	111

A.1.2.10	Isolated guinea pig ureter	115
A.1.2.11	Isolated corpus cavernosum	116
A.1.3	Cardiovascular analysis <i>in vivo</i>	118
A.1.3.1	Hemodynamic screening in anesthetized rats	118
A.1.3.2	Blood pressure in pithed rats	120
A.1.3.3	Antihypertensive vasodilator activity in ganglion-blocked, angiotensin II supported rats	121
A.1.3.4	Blood pressure in conscious hypertensive rats (tail cuff method) ..	122
A.1.3.5	Direct measurement of blood pressure in conscious rats with indwelling catheter	123
A.1.3.6	Cannulation techniques in rodents	125
A.1.3.6.1	Permanent cannulation of the jugular vein in rats	126
A.1.3.6.2	Permanent cannulation of the renal vein in rats	126
A.1.3.6.3	Permanent cannulation of the portal vein in rats	127
A.1.3.6.4	Permanent cannulation of the thoracic duct in rats	127
A.1.3.6.5	Portacaval anastomosis in rats	128
A.1.3.7	Cardiovascular analysis in anesthetized mice	129
A.1.3.8	Blood pressure in anesthetized cats	130
A.1.3.9	Cardiovascular drug challenging experiments in anesthetized dogs ..	131
A.1.3.10	Hemodynamic analysis in anaesthetized dogs	131
A.1.3.11	Hemodynamic measurements in conscious dogs	134
A.1.3.12	Hemodynamic studies in monkeys	135
A.1.3.13	Measurement of cardiac output and regional blood flow with microspheres	136
A.1.3.14	Carotid artery loop technique	137
A.1.3.15	Measurement of heart dimensions in anesthetized dogs	138
A.1.3.16	Telemetric monitoring of cardiovascular parameters in rats	139
A.1.3.17	Cardiovascular effects after intracerebroventricular administration	142
A.1.3.18	Influence on orthostatic hypotension	142
A.1.3.19	Bezold-Jarisch reflex	143
A.1.3.20	Endotoxin induced shock	145
A.1.3.21	Hemorrhagic shock	146
A.1.3.22	Tourniquet shock	147
A.1.3.23	Heat stroke	148
A.1.3.24	α - and β -adrenoreceptors in the mouse iris	149
A.1.3.25	α_2 -adrenoreceptor blockade measured <i>in vivo</i> by clonidine-induced sleep in chicks	151
A.1.3.26	Activity at β_1 - and β_2 -adrenoreceptors in the rat	151
A.1.3.27	β_1 - and β_2 -Sympatholytic activity in dogs	152
A.1.3.28	Intrinsic β -sympathomimetic activity in reserpine-pretreated dogs ..	154
A.1.3.29	Cat nictitating membrane preparation (ganglion blocking activity) ..	154
A.1.3.30	Assessment of ganglion-blocking activity in the isolated bovine retractor penis muscle	156
A.1.3.31	Angiotensin II antagonism	158
A.1.3.32	ACE inhibition measured <i>in vivo</i> in the rat	161
A.1.3.33	Evaluation of renin inhibitors in dogs	162
A.1.3.34	Evaluation of renin inhibitors in monkeys	164
A.1.4	Cardiovascular safety studies	165
A.1.4.1	General considerations	165
A.1.4.2	Cardiovascular safety studies in dogs and other species	166
A.1.4.3	Monophasic action potentials in dogs	168
A.1.4.4	Studies of arrhythmogenic effects in isolated heart preparations ..	168
A.1.4.5	Studies in isolated Purkinje fibres	169
A.1.4.6	Studies in isolated ventricular myocytes	170

A.2	Methods to induce experimental hypertension	172
A.2.0.1	Acute renal hypertension in rats	172
A.2.0.2	Chronic renal hypertension in rats	172
A.2.0.3	Chronic renal hypertension in dogs	173
A.2.0.4	Neurogenic hypertension in dogs	174
A.2.0.5	DOCA-salt induced hypertension in rats	175
A.2.0.6	Fructose induced hypertension in rats	176
A.2.0.7	Genetic hypertension in rats	176
A.2.0.8	Pulmonary hypertension induced by monocrotaline	179
A.3	Coronary drugs	180
A.3.1	Isolated organs	180
A.3.1.1	Heart-lung preparation	180
A.3.1.2	Isolated heart according to LANGENDORFF	183
A.3.1.3	Coronary artery ligation in isolated working rat heart	188
A.3.1.4	Relaxation of bovine coronary artery	190
A.3.2	<i>In vivo</i> methods	191
A.3.2.1	Isoproterenol induced myocardial necrosis in rats	191
A.3.2.2	Myocardial infarction after coronary ligation	192
A.3.2.3	Occlusion of coronary artery in anesthetized dogs	194
A.3.2.4	Acute ischemia by injection of microspheres in dogs	196
A.3.2.5	Influence on myocardial preconditioning	198
A.3.3	<i>Ex vivo</i> methods	200
A.3.3.1	Plastic casts from coronary vasculature bed	200
A.4	Calcium uptake inhibiting activity	201
A.4.0.1	General considerations	201
A.4.1	<i>In vitro</i> methods	203
A.4.1.1	³ H-nitrendipine binding <i>in vitro</i>	203
A.4.2	Isolated organs	203
A.4.2.1	Calcium antagonism on action potential of isolated guinea pig papillary muscle	205
A.4.2.2	Calcium antagonism in the isolated guinea pig atrium	206
A.4.2.3	Calcium antagonism in the isolated rabbit aorta	207
A.4.2.4	Calcium antagonism in the isolated guinea pig pulmonary artery	208
A.4.3	<i>In vivo</i> methods	209
A.4.3.1	Evaluation of calcium blockers in the pithed rat	209
A.5	Anti-arrhythmic activity	209
A.5.0.1	General considerations	209
A.5.0.2	Electrocardiography in animals	211
A.5.0.3	Aconitine antagonism in rats	213
A.5.0.4	Digoxin-induced ventricular arrhythmias in anesthetized guinea pigs	215
A.5.0.5	Strophanthin or ouabain induced arrhythmia	215
A.5.0.6	Ventricular fibrillation electrical threshold	216
A.5.0.7	Coronary artery ligation, reperfusion arrhythmia and infarct size in rats	217
A.5.0.8	Ventricular arrhythmia after coronary occlusion	220
A.5.0.8.1	Ventricular fibrillation after coronary occlusion and reperfusion in anesthetized dogs	220
A.5.0.8.2	Harris dog model of ventricular tachycardia	222
A.5.0.8.3	Protection against sudden coronary death	223
A.5.0.8.4	Ventricular fibrillation induced by cardiac ischemia during exercise	224

A.5.0.9	Characterization of anti-arrhythmic activity in the isolated right ventricular guinea pig papillary muscle	226
A.5.0.10	Action potential and refractory period in isolated left ventricular guinea pig papillary muscle	227
A.6	Methods to induce cardiac hypertrophy and insufficiency	229
A.6.0.1	Aortic banding in rats	229
A.6.0.2	Cardiac hypertrophy in mice	231
A.6.0.3	Cardiac insufficiency in guinea pigs	231
A.6.0.4	Cardiomyopathic Syrian hamster	233
A.6.0.5	Hypertrophy of cultured cardiac cells	234
A.7	Positive inotropic activity (cardiac glycosides)	235
A.7.0.1	General considerations	235
A.7.1	<i>In vitro</i> tests	236
A.7.1.1	Ouabain binding	236
A.7.1.2	Influence on Na ⁺ /K ⁺ ATPase	237
A.7.2	Tests in isolated tissues and organs	238
A.7.2.1	Isolated cat papillary muscle	238
A.7.2.2	Isolated hamster cardiomyopathic heart	239
A.7.2.3	Potassium loss from the isolated guinea pig heart	240
A.7.3	<i>In vivo</i> tests	241
A.7.3.1	Cardiac toxicity in cats (Hatcher's method)	241
A.7.3.2	Decay rate and enteral absorption rate of cardiac glycosides	241
A.8	Effects on blood supply and on arterial and venous tonus	242
A.8.1	Models for stroke and multi-infarct cerebral dysfunction	242
A.8.1.1	Cerebral ischemia by carotid artery occlusion in Mongolian gerbils	242
A.8.1.2	Forebrain ischemia in rats	244
A.8.1.3	Hypoxia tolerance test in rats	245
A.8.1.4	Middle cerebral artery occlusion in rats	246
A.8.1.5	Photochemically induced focal cerebral ischemia in rats	249
A.8.1.6	Microdialysis and neuroprotection experiments after global ischemia in rats	250
A.8.1.7	Hypoxia/hypoglycemia in hippocampal slices	251
A.8.1.8	Measurement of local cerebral blood flow and glucose utilization in rats	252
A.8.1.9	Cerebrovascular resistance in anesthetized baboons	253
A.8.1.10	Effect on cerebral blood flow in cats (Fluorography)	255
A.8.1.11	Effect on cerebral blood flow and in ischemic skeletal muscle in rats (Laser-Doppler-Effect)	256
A.8.1.12	Traumatic brain injury	257
A.8.2	Peripheral blood supply	259
A.8.2.1	Perfused hindquarter preparation with sympathetic nerve stimulation in rats	259
A.8.2.2	Effect on peripheral blood flow in rats	261
A.8.2.3	Effect on peripheral blood flow in anesthetized dogs	262
A.8.2.4	Effect on peripheral blood supply measured by local oxygen pressure	263
A.8.2.5	Effect on mesenteric blood flow in rats	264
A.8.2.6	Effect on pulmonary blood flow	266
A.8.2.7	Effect on contractile force of ischemic muscle	267
A.8.2.8	Effect on perfusion of rabbit ear (Pissemiski method)	268
A.8.2.9	Effect on venous tonus <i>in situ</i> in dogs	270

A.8.3	Angiogenesis and anti-angiogenesis	270
A.8.3.1	General considerations	270
A.8.3.2	Endothelial cell proliferation	271
A.8.3.3	Chorioallantoic membrane assay	272
A.8.3.4	Cornea neovascularization	273
A.8.3.5	Rat subcutaneous air sac model	275
A.8.3.6	Mesenteric window angiogenesis model	276

Chapter B

Activity on blood constituents	277
---	-----

B.1	<i>In vitro</i> tests	277
B.1.1	Blood coagulation tests	277
B.1.2	Thrombelastography	278
B.1.3	Chandler loop	280
B.1.4	Platelet aggregation and deaggregation in platelet rich plasma or washed platelets (BORN method)	280
B.1.5	Platelet aggregation after gel filtration	282
B.1.6	Platelet aggregation in whole blood	283
B.1.7	Euglobulin lysis time	284
B.1.8	Fibrinogen receptor binding	285
B.1.9	PAF antagonism	286
B.1.10	Flow behavior of erythrocytes	287
B.1.11	Filterability of erythrocytes	287
B.1.12	Erythrocyte aggregation	288
B.1.13	Determination of plasma viscosity	289
B.2	<i>In vivo</i> or <i>ex vivo</i> models	289
B.2.1	Stenosis- and mechanical injury-induced coronary thrombosis (Folts-model)	290
B.2.2	Stenosis-and mechanical injury-induced arterial and venous thrombosis (Harbauer-model)	294
B.2.3	Electrical-induced thrombosis	296
B.2.4	FeCl ₃ -induced thrombosis	297
B.2.5	Laser-induced thrombosis	298
B.2.6	Photochemical-induced thrombosis	299
B.2.7	Foreign-surface thrombosis	299
B.2.7.1	Wire-coil induced thrombosis	299
B.2.7.2	Eversion-graft induced thrombosis	300
B.2.7.3	Arterio-venous shunt thrombosis	301
B.2.7.4	Thread-induced venous thrombosis	302
B.2.7.5	Thrombus formation on superfused tendon	303
B.2.8	Stasis-induced thrombosis (Wessler-model)	303
B.2.9	Experimental thrombocytopenia or leucocytopenia	305
B.2.10	Collagenase-induced thrombocytopenia	306
B.2.11	Reversible intravital aggregation of platelets	306
B.3	Bleeding models	307
B.3.1	Subaqueous tail bleeding time in rodents	307
B.3.2	Arterial bleeding time in mesentery	308
B.3.3	Template Bleeding Time Method	308
B.4	Genetically modified animals	309
B.4.1	Knock out mice	309

Chapter C		
Activity on urinary tract		317
C.1 Diuretic and saluretic activity		317
C.1.1 <i>In vitro</i> methods		317
C.1.1.1 Carbonic anhydrase inhibition <i>in vitro</i>		317
C.1.1.2 Patch clamp technique in kidney cells		319
C.1.1.3 Perfusion of isolated kidney tubules		320
C.1.1.4 Isolated perfused kidney		322
C.1.2 <i>In vivo</i> methods		323
C.1.2.1 Diuretic activity in rats (LIPSCHITZ test)		323
C.1.2.2 Saluretic activity in rats		324
C.1.2.3 Diuretic and saluretic activity in dogs		325
C.1.2.4 Clearance methods		326
C.1.2.5 Micropuncture techniques in the rat		327
C.1.2.6 Stop-flow technique		328
C.2 Impaired renal function		328
C.2.1 Chronic renal failure in the rat		328
C.2.2 Chronic renal failure after subtotal (five-sixths) nephrectomy in rats		329
C.2.3 Experimental nephritis		333
C.2.3.1 General considerations		333
C.2.3.2 Nephrotoxic serum nephritis		333
C.2.4 Experimental nephrosis		336
C.3 Uricosuric and hypo-uricemic activity		337
C.3.1 <i>In vitro</i> methods		337
C.3.1.1 Inhibition of xanthine oxidase <i>in vitro</i> indicating hypouricemic activity		337
C.3.1.2 Urate uptake in brush border membrane vesicles		337
C.3.2 <i>In vivo</i> methods		338
C.3.2.1 Diuretic and uricosuric activity in mice		338
C.3.2.2 Hypouricemic activity after allantoxanamide treatment in rats		339
C.3.2.3 Hypouricemic and uricosuric activity after potassium oxonate treatment in rats		339
C.3.2.4 Phenol red excretion in rats		340
C.3.2.5 Uricosuric activity in Dalmatian dogs		340
C.3.2.6 Uricosuric activity in Cebus monkeys		341
C.4 Influence on lower urinary tract		342
C.4.1 <i>In vivo</i> studies		342
C.4.1.1 Micturition studies		342
C.4.2 Studies in isolated organs		344
C.4.2.1 Studies on renal pelvis		344
C.4.2.2 Studies on urinary bladder and internal urethral sphincter		345
C.4.2.3 Effects on external urethral sphincter		348
C.4.2.4 Propagation of impulses in the guinea pig ureter		348
Chapter D		
Respiratory activity		351
D.1 <i>In vitro</i> tests		351
D.1.0.1 Histamine (H ₁) receptor binding		352

D.2	Effects on air ways	352
D.2.1	Tests in isolated organs	352
D.2.1.1	Spasmolytic activity in isolated guinea pig lung strips	352
D.2.1.2	Spasmolytic activity in isolated trachea	353
D.2.1.3	Reactivity of the isolated perfused trachea	355
D.2.1.4	Bronchial perfusion of isolated lung	357
D.2.1.5	Vascular and airway responses in the isolated lung	357
D.2.2	<i>In vivo</i> tests	359
D.2.2.1	Bronchospasmolytic activity in anesthetized guinea pigs (Konzett-Rössler method)	359
D.2.2.2	Effect of arachidonic acid or PAF on respiratory function <i>in vivo</i>	361
D.2.2.3	Bronchial hyperreactivity	362
D.2.2.4	Body plethysmography and respiratory parameters after histamine-induced bronchoconstriction in anesthetized guinea pigs	364
D.2.2.5	Pneumotachography in anesthetized guinea pigs	366
D.2.2.6	Airway microvascular leakage	368
D.2.2.7	Isolated larynx <i>in situ</i>	369
D.2.2.8	Safety pharmacology of the respiratory system	370
D.2.2.8.1	Effects of respiratory depressant drugs in conscious rats	371
D.2.2.8.2	Pulmonary function in unanesthetized dogs	372
D.3	Antitussive activity	373
D.3.0.1	Antitussive activity after irritant inhalation in guinea pigs	373
D.3.0.2	Cough induced by mechanical stimulation	374
D.3.0.3	Cough induced by stimulation of the nervus laryngicus superior	375
D.4	Effects on tracheal cells and bronchial mucus secretion and transport	376
D.4.0.1	<i>In vitro</i> studies of mucus secretion	376
D.4.0.2	Acute studies of mucus secretion	377
D.4.0.3	Studies of mucus secretion with chronic cannulation	378
D.4.0.4	Bronchoalveolar lavage	379
D.4.0.5	Ciliary activity	380
D.4.0.6	Studies of mucociliary transport	381
D.4.0.7	Culture of tracheal epithelial cells	383
 Chapter E		
	Psychotropic and neurotropic activity	385
E.1	Effects on behavior and muscle coordination	388
E.1.1	Spontaneous behavior	388
E.1.1.1	General considerations	388
E.1.1.2	Observational assessment	388
E.1.1.3	Safety pharmacology core battery	389
E.1.2	Effects on motility (sedative or stimulatory activity)	390
E.1.2.1	General considerations	390
E.1.2.2	Method of intermittent observations	390
E.1.2.3	Open field test	391
E.1.2.4	Hole-board test	393
E.1.2.5	Combined open field test	394
E.1.2.6	EEG analysis from rat brain by telemetry	395
E.1.3	Tests for muscle coordination	396

E.1.3.1	Inclined plane	396
E.1.3.2	Chimney test	396
E.1.3.3	Grip strength	397
E.1.3.4	Rotarod method	398
E.1.3.5	Influence on polysynaptic reflexes	398
E.1.3.6	Masticatory muscle reflexes	400
E.2	Tests for anxiolytic activity	401
E.2.0.1	General considerations	401
E.2.1	<i>In vitro</i> methods	402
E.2.1.1	<i>In vitro</i> assay for GABAergic compounds: [³ H]-GABA receptor binding	402
E.2.1.2	GABA _A receptor binding	403
E.2.1.3	GABA _B receptor binding	406
E.2.1.4	Benzodiazepine receptor: [³ H]-flunitrazepam binding assay	408
E.2.1.5	Serotonin receptor binding	410
E.2.1.5.1	General considerations	410
E.2.1.5.2	Serotonin (5HT _{1A}) receptor: binding of [³ H]-8-hydroxy-2-(di-n-propylamino)-tetralin ([³ H]-DPAT)	414
E.2.1.5.3	Serotonin (5HT _{1B}) receptors in brain: binding of [³ H]5-hydroxytryptamine ([³ H]5HT)	417
E.2.1.5.4	5HT ₃ receptor in rat entorhinal cortex membranes: binding of [³ H]GR 65630	419
E.2.1.6	Histamine H ₃ receptor binding in brain	421
E.2.2	Anticonvulsant activity	422
E.2.2.1	Pentylenetetrazole (Metrazol) induced convulsions	422
E.2.2.2	Strychnine-induced convulsions	423
E.2.2.3	Picrotoxin-induced convulsions	424
E.2.2.4	Isoniazid-induced convulsions	424
E.2.2.5	Yohimbine-induced convulsions	425
E.2.3	Anti-aggressive activity	425
E.2.3.1	Foot-shock induced aggression	425
E.2.3.2	Isolation-induced aggression	426
E.2.3.3	Resident-intruder aggression test	427
E.2.3.4	Water competition test	428
E.2.3.5	Maternal aggression in rats	428
E.2.3.6	Rage reaction in cats	430
E.2.4	Effects on behavior	430
E.2.4.1	Anti-anxiety test (light-dark model)	430
E.2.4.2	Anticipatory anxiety in mice	431
E.2.4.3	Social interaction in rats	432
E.2.4.4	Elevated plus maze test	434
E.2.4.5	Water maze test	435
E.2.4.6	Staircase test	436
E.2.4.7	Cork gnawing test in the rat	437
E.2.4.8	Distress vocalization in rat pups	437
E.2.4.9	Schedule induced polydipsia in rats	438
E.2.4.10	Four plate test in mice	439
E.2.4.11	Footshock induced freezing behavior in rats	439
E.2.4.12	Experimental anxiety in mice	440
E.2.4.13	mCPP induced anxiety in rats	441
E.2.4.14	Acoustic startle response in rats	442
E.2.4.15	Unconditioned conflict procedure (Vogel test)	443
E.2.4.16	Novelty-suppressed feeding	444
E.2.4.17	Shock probe conflict procedure	445

E.2.4.18	Ultrasound induced defensive behavior in rats	445
E.2.4.19	Anxiety/defense test battery in rats	446
E.2.4.20	Marmoset human threat test	447
E.2.4.21	Aversive brain stimulation	448
E.2.5	Conditioned behavioral responses	450
E.2.5.1	Sidman avoidance paradigm	450
E.2.5.2	Geller conflict paradigm	451
E.2.5.3	Conditioned defensive burying in rats	453
E.2.5.4	Taste aversion paradigm	454
E.2.6	Effects on the endocrine system	456
E.2.6.1	Plasma catecholamine levels during and after stress	456
E.2.6.2	Plasma corticosterone levels influenced by psychotropic drugs	457
E.2.7	Benzodiazepine dependence	458
E.2.7.1	General considerations	458
E.2.7.2	Benzodiazepine tolerance and dependence in rats	458
E.3	Anti-epileptic activity	459
E.3.0.1	General considerations	459
E.3.1	<i>In vitro</i> methods	460
E.3.1.1	³ H-GABA receptor binding	460
E.3.1.2	GABA _A receptor binding	460
E.3.1.3	GABA _B receptor binding	460
E.3.1.4	³ H-GABA uptake in rat cerebral cortex synaptosomes	461
E.3.1.5	GABA uptake and release in rat hippocampal slices	462
E.3.1.6	Glutamate receptors: [³ H]CPP binding	463
E.3.1.7	NMDA receptor complex: [³ H]TCP binding	466
E.3.1.8	Metabotropic glutamate receptors	470
E.3.1.9	Excitatory amino acid transporters	473
E.3.1.10	[³⁵ S]TBPS binding in rat cortical homogenates and sections	474
E.3.1.11	[³ H]glycine binding in rat cerebral cortex	476
E.3.1.12	[³ H]strychnine sensitive glycine receptor	478
E.3.1.13	Electrical recordings from hippocampal slices <i>in vitro</i>	479
E.3.1.14	Electrical recordings isolated brain cells	481
E.3.1.15	Isolated neonatal rat spinal cord	482
E.3.1.16	Cell culture of neurons	484
E.3.2	<i>In vivo</i> methods	487
E.3.2.1	Electroshock in mice	487
E.3.2.2	Pentylenetetrazol test in mice and rats	487
E.3.2.3	Strychnine-induced convulsions in mice	487
E.3.2.4	Picrotoxin-induced convulsions in mice	488
E.3.2.5	Isoniazid-induced convulsions in mice	488
E.3.2.6	Bicuculline test in rats	488
E.3.2.7	4-aminopyridine-induced seizures in mice	488
E.3.2.8	Epilepsy induced by focal lesions	489
E.3.2.9	Kindled rat seizure model	491
E.3.2.10	Posthypoxic myoclonus in rats	492
E.3.2.11	Genetic animal models of epilepsy	493
E.4	Hypnotic activity	495
E.4.0.1	General considerations	495
E.4.1	<i>In vivo</i> methods	495
E.4.1.1	Potentiation of hexobarbital sleeping time	495
E.4.1.2	Experimental insomnia in rats	496
E.4.1.3	EEG registration in conscious cats	497
E.4.1.4	Automated rat sleep analysis system	499

E.5	Neuroleptic activity	500
E.5.0.1	General considerations	500
E.5.1	<i>In vitro</i> methods	500
E.5.1.1	D ₁ Receptor assay: [³ H]-SCH 23390 binding to rat striatal homogenates	500
E.5.1.2	D ₂ Receptor assay: [³ H]-spiperidol binding	502
E.5.1.3	Dopamine D ₂ receptor autoradiography (³ H-Spiperone binding)	504
E.5.1.4	Binding to the D ₃ receptor	506
E.5.1.5	Binding to D ₄ receptors	507
E.5.1.6	Determination of dopamine autoreceptor activity	509
E.5.1.7	Dopamine-sensitive adenylate cyclase in rat striatum	510
E.5.1.8	α ₁ -adrenergic receptor binding in brain	511
E.5.1.9	[³ H]Spiperidol binding to 5HT ₂ receptors in rat cerebral cortex	512
E.5.1.10	Serotonin 5HT ₂ receptor autoradiography (³ H-Spiperone binding)	514
E.5.1.11	Binding to the sigma receptor	516
E.5.1.12	Simultaneous determination of norepinephrine, dopamine, DOPAC, HVA, HIAA, and 5-HT from rat brain areas	518
E.5.1.13	Measurement of neurotransmitters by intracranial microdialysis	519
E.5.1.14	Use of push-pull cannulae to determine the release of endogenous neurotransmitters	522
E.5.1.15	Fos protein expression in brain	524
E.5.1.16	Neurotensin	525
E.5.1.16.1	General considerations on neurotensin and neurotensin receptors	525
E.5.1.16.2	Neurotensin receptor binding	527
E.5.2	Behavioral tests	529
E.5.2.1	Golden hamster test	529
E.5.2.2	Influence on behavior of the cotton rat	530
E.5.2.3	Artificial hibernation in rats	531
E.5.2.4	Catalepsy in rodents	531
E.5.2.5	Pole climb avoidance in rats	532
E.5.2.6	Foot-shock induced aggression	533
E.5.2.7	Brain self stimulation	533
E.5.3	Tests based on the mechanism of action	534
E.5.3.1	Amphetamine group toxicity	534
E.5.3.2	Inhibition of amphetamine stereotypy in rats	535
E.5.3.3	Inhibition of apomorphine climbing in mice	536
E.5.3.4	Inhibition of apomorphine stereotypy in rats	537
E.5.3.5	Yawning/penile erection syndrome in rats	538
E.5.3.6	Inhibition of mouse jumping	540
E.5.3.7	Antagonism against MK-801 induced locomotion and falling in mice	540
E.5.3.8	Inhibition of apomorphine-induced emesis in the dog	541
E.5.3.9	Purposeless chewing in rats	541
E.5.3.10	Single unit recording of A9 and A10 midbrain dopaminergic neurons	542
E.5.3.11	<i>In vivo</i> voltammetry	543
E.6	Antidepressant activity	545
E.6.0.1	General considerations	545
E.6.1	<i>In vitro</i> methods	546
E.6.1.1	Inhibition of [³ H]-norepinephrine uptake in rat brain synaptosomes	546
E.6.1.2	Inhibition of [³ H]-dopamine uptake in rat striatal synaptosomes	546
E.6.1.3	Inhibition of [³ H]-serotonin uptake in synaptosomes	548
E.6.1.4	Binding to monoamine transporters	549

E.6.1.5	Antagonism of p-chloramphetamine toxicity by inhibitors of serotonin uptake	551
E.6.1.6	Receptor subsensitivity after treatment with antidepressants	552
E.6.1.7	Measurement of β -adrenoreceptor stimulated adenylate cyclase ..	554
E.6.1.8	[³ H]Yohimbine binding to α_2 -adrenoceptors in rat cerebral cortex	555
E.6.1.9	Test for anticholinergic properties by [³ H]-QNB binding to muscarinic cholinergic receptors in rat brain	556
E.6.1.10	Monoamine oxidase inhibition: Inhibition of type A and type B monoamine oxidase activities in rat brain synaptosomes	557
E.6.2	Behavioral tests	558
E.6.2.1	Catalepsy antagonism in chicken	558
E.6.2.2	Despair swim test	559
E.6.2.3	Tail suspension test in mice	561
E.6.2.4	Learned helplessness in rats	561
E.6.2.5	Muricide behavior in rats	562
E.6.2.6	Behavioral changes after neonatal clomipramine treatment	563
E.6.2.7	Antidepressant-like activity in differential-reinforcement of low rate 72-second schedule	565
E.6.3	Tests for antidepressant activity based on the mechanism of action	566
E.6.3.1	Potentialiation of norepinephrine toxicity	566
E.6.3.2	Compulsive gnawing in mice	567
E.6.3.3	Apomorphine- induced hypothermia in mice	567
E.6.3.4	Tetrabenazine antagonism in mice	568
E.6.3.5	Reserpine induced hypothermia	569
E.6.3.6	5-Hydroxytryptophan potentiation in mice	570
E.6.3.7	5-Hydroxytryptophan potentiation in rats	571
E.6.3.8	Yohimbine toxicity enhancement	571
E.6.3.9	Tryptamine seizure potentiation in rats	572
E.6.3.10	Serotonin syndrome in rats	572
E.6.3.11	Hypermotility in olfactory-bulbectomized rats	574
E.6.3.12	Sexual behavior in male rats	575
E.7	Anti-Parkinsonism activity	577
E.7.0.1	General considerations	577
E.7.1	<i>In vivo</i> methods	577
E.7.1.1	Tremorine and oxotremorine antagonism	577
E.7.1.2	MPTP model in monkeys	579
E.7.1.3	Reserpine antagonism	580
E.7.1.4	Circling behavior in nigrostriatal lesioned rats	581
E.7.1.5	Elevated body swing test	583
E.7.1.6	Skilled paw reaching in rats	583
E.7.1.7	Stepping test in rats	585
E.8	General anesthesia	586
E.8.1	Intravenous anesthesia	586
E.8.1.1	General considerations	586
E.8.1.2	Screening of intravenous anesthetics	587
E.8.1.3	EEG threshold test in rats	588
E.8.1.4	Efficacy and safety of intravenous anesthetics	589
E.8.2	Inhalation anesthesia	589
E.8.2.1	General considerations	589
E.8.2.2	Screening of volatile anesthetics	590
E.8.2.3	Efficacy and safety of inhalation anesthetics	591

Chapter F		
Drug effects on learning and memory		595
F.1	Introduction	595
F.2	<i>In vitro</i> methods	599
F.2.0.1	<i>In vitro</i> inhibition of acetylcholine-esterase activity in rat striatum	599
F.2.0.2	<i>In vitro</i> inhibition of butyrylcholine-esterase activity in human serum	601
F.2.0.3	<i>Ex vivo</i> cholinesterase inhibition	601
F.2.0.4	Molecular forms of acetylcholinesterase from rat frontal cortex and striatum	603
F.2.0.5	Release of [³ H]ACh and other transmitters from rat brain slices	605
F.2.0.6	[³ H]oxotremorine-M binding to muscarinic cholinergic receptors in rat forebrain	608
F.2.0.7	[³ H]-N-methylscopolamine binding in the presence and absence of Gpp(NH)p	610
F.2.0.8	Stimulation of phosphatidylinositol turnover in rat brain slices	611
F.2.0.9	[³ H]-N-methylcarbamylcholine binding to nicotinic cholinergic receptors in rat frontal cortex	613
F.2.0.10	Cultured neurons/astroglial cells	615
F.2.0.11	Inhibition of respiratory burst in microglial cells/macrophages	618
F.3	<i>In vivo</i> methods	619
F.3.1	Inhibitory (passive) avoidance	619
F.3.1.1	Step-down	619
F.3.1.2	Step-through	620
F.3.1.3	Two compartment test	621
F.3.1.4	Up-hill avoidance	621
F.3.1.5	Trial-to-criteria inhibitory avoidance	622
F.3.1.6	Scopolamine-induced amnesia in mice	623
F.3.1.7	Memory impairment by basal forebrain lesions in rats	624
F.3.1.8	Ischemia-induced amnesia in gerbils	624
F.3.1.9	Cognitive deficits on chronic low dose MPTP-treated monkeys	625
F.3.2	Active avoidance	626
F.3.2.1	Runway avoidance	626
F.3.2.2	Shuttle box avoidance (two-way shuttle box)	627
F.3.2.3	Jumping avoidance (one-way shuttle box)	627
F.3.3	Discrimination learning	628
F.3.3.1	Spatial habituation learning	628
F.3.3.2	Spatial discrimination	629
F.3.3.3	Spatial learning in the radial arm maze	630
F.3.3.4	Visual discrimination	631
F.3.3.5	Spatial learning in the water maze	632
F.3.3.6	Olfactory learning	633
F.3.3.7	Aversive discrimination in chickens	634
F.3.4	Conditioned responses	636
F.3.4.1	Conditioned nictitating membrane response in rabbits	636
F.3.4.2	Automated learning and memory model in mice	637
F.3.5	Studies in aged monkeys	639
F.3.6	Electrophysiological methods	639
F.3.6.1	Long-term potentiation in hippocampal slices	639
F.3.6.2	Long term potentiation <i>in vivo</i>	641
F.3.6.3	Long latency averaged potentials	642
F.3.7	Metabolic influence	643
F.3.7.1	Sodium nitrite intoxication (NaNO ₂)	643

Chapter G**Effects on peripheral nerve function 645**

G.1	Local anesthetic activity	645
G.1.0.1	General considerations	645
G.1.1	Conduction anesthesia	646
G.1.1.1	Conduction anesthesia in the sciatic nerve of the frog	646
G.1.1.2	Conduction anesthesia in the sciatic nerve of the rat	647
G.1.1.3	Conduction anesthesia on the mouse tail	648
G.1.1.4	Rabbit tooth pulp assay	649
G.1.1.5	Retrobulbar block in dogs	650
G.1.1.6	Isolated sciatic nerve preparation of the frog	650
G.1.1.7	Isolated mammalian sciatic nerve preparation	652
G.1.1.8	Effect of local anesthetics on different nerve fibres	653
G.1.1.9	Measurement of sodium and potassium conductance in voltage clamp experiments	654
G.1.2	Infiltration anesthesia	655
G.1.2.1	Infiltration anesthesia in guinea pig's wheals	655
G.1.3	Surface anesthesia	655
G.1.3.1	Surface anesthesia on the cornea of rabbits	655
G.1.3.2	Suppression of sneezing reflex in rabbits	656
G.1.4	Epidural anesthesia	657
G.1.4.1	Epidural anesthesia in guinea pigs	657
G.1.5	Intrathecal (spinal) anesthesia	658
G.1.5.1	Spinal anesthesia in rats	658
G.1.5.2	Blockade of urethral reflex in rabbits	660
G.1.6	Endoanesthetic effect	660
G.1.7	Effect on electroretinogram	662
G.2	Neuromuscular blocking activity	663
G.2.0.1	General considerations	663
G.2.0.2	Isolated phrenic nerve diaphragm preparation of the rat	664
G.2.0.3	Sciatic nerve-gastrocnemius muscle preparation in the rabbit	666
G.2.0.4	Evaluation of neuromuscular blockade in anesthetized mice	668

Chapter H**Analgesic, anti-inflammatory, and anti-pyretic activity 669**

H.1	Central analgesic activity	670
H.1.0.1	General considerations	670
H.1.1	<i>In vitro</i> methods for central analgesic activity	671
H.1.1.1	Survey	671
H.1.1.2	³ H-Naloxone binding assay	674
H.1.1.3	³ H-Dihydromorphine binding to μ opiate receptors in rat brain ...	675
H.1.1.4	³ H-Bremazocine binding to κ opiate receptors in guinea pig cerebellum	676
H.1.1.5	Inhibition of enkephalinase	677
H.1.1.6	Nociceptin	678
H.1.1.6.1	General considerations on nociceptin	678
H.1.1.6.2	Receptor binding of nociceptin	679
H.1.1.6.3	Bioassays for nociceptin	681
H.1.1.7	Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP)	682
H.1.1.8	Cannabinoid activity	684

H.1.1.8.1	General considerations on cannabinoids	684
H.1.1.8.2	Receptor binding of cannabinoids	686
H.1.1.9	Vanilloid (capsaicin) activity	688
H.1.1.9.1	General considerations on vanilloids	688
H.1.1.9.2	Vanilloid receptor binding	690
H.1.1.9.3	Evaluation of vanilloid receptor antagonists	691
H.1.2	<i>In vivo</i> methods for testing central analgesic activity	692
H.1.2.1	General considerations	692
H.1.2.2	HAFFNER's tail clip method	693
H.1.2.3	Radiant heat method	694
H.1.2.4	Hot plate method	696
H.1.2.5	Tail immersion test	697
H.1.2.6	Electrical stimulation of the tail	698
H.1.2.7	Grid shock test	699
H.1.2.8	Tooth pulp stimulation	700
H.1.2.9	Monkey shock titration test	702
H.1.2.10	Formalin test in rats	702
H.1.2.11	Experimental neuropathy	704
H.1.3	Side effects of central analgesic drugs	706
H.1.3.1	General considerations	706
H.1.3.2	Test for respiratory depression	706
H.1.3.3	Decrease of body temperature	707
H.1.3.4	Methods for the study of tolerance	707
H.1.3.5	Tests for physical dependence	708
H.1.3.6	Tests for addiction liability	710
H.1.3.6.1	General considerations	710
H.1.3.6.2	Drug discrimination studies	710
H.1.3.6.3	Place conditioning paradigm	713
H.2	Peripheral analgesic activity	716
H.2.0.1	General considerations	716
H.2.0.2	Writhing tests	716
H.2.0.3	Pain in inflamed tissue (RANDALL-SELITTO-test)	717
H.2.0.4	Mechanical visceral pain model in the rat	720
H.2.0.5	Antagonism against local effects of bradykinin	721
H.2.0.6	Effect of analgesics on spinal neurons	723
H.3	Anti-inflammatory activity	725
H.3.0.1	General considerations	725
H.3.1	<i>In vitro</i> methods for anti-inflammatory activity	726
H.3.1.1	General considerations	726
H.3.1.2	³ H-Bradykinin receptor binding	726
H.3.1.3	Substance P and the tachykinin family	728
H.3.1.3.1	General considerations	728
H.3.1.3.2	³ H-Substance P receptor binding	730
H.3.1.3.3	Neurokinin receptor binding	731
H.3.1.3.4	Characterization of neurokinin agonists and antagonists by biological assays	733
H.3.1.4	Assay of polymorphonuclear leukocyte chemotaxis <i>in vitro</i>	735
H.3.1.5	Polymorphonuclear leukocytes aggregation induced by FMLP	737
H.3.1.6	Constitutive and inducible cellular arachidonic acid metabolism <i>in vitro</i>	737
H.3.1.6.1	Formation of leukotriene B ₄ in human white blood cells <i>in vitro</i> ..	738
H.3.1.6.2	Formation of lipoxygenase products from ¹⁴ C-arachidonic acid in human polymorphonuclear neutrophils (PMN) <i>in vitro</i>	738

H.3.1.6.3	Formation of eicosanoids from ¹⁴ C-arachidonic acid in human platelets <i>in vitro</i>	738
H.3.1.6.4	Stimulation of inducible prostaglandin pathway in human PMNL ...	739
H.3.1.6.5	COX-1 and COX-2 inhibition	740
H.3.1.7	Induced release of cytokines (Interleukin-1alpha, IL-1beta, IL-6, IL-8 and TNF-alpha) from human white blood cells <i>in vitro</i>	744
H.3.1.8	Flow cytometric analysis of intracellular cytokines	745
H.3.1.9	TNF-alpha antagonism	746
H.3.1.10	Binding to interferon receptors	747
H.3.1.11	Screening for interleukin-1 antagonists	748
H.3.1.12	Inhibition of interleukin-1 β converting enzyme (ICE)	750
H.3.2	<i>In vivo</i> methods for anti-inflammatory activity	751
H.3.2.1	General considerations	751
H.3.2.2	Methods for testing acute and subacute inflammation	752
H.3.2.2.1	Ultraviolet erythema in guinea pigs	752
H.3.2.2.2	Vascular permeability	753
H.3.2.2.3	Inhibition of leukocyte adhesion to rat mesenteric venules <i>in vivo</i> ...	755
H.3.2.2.4	Oxazolone-induced ear edema in mice	756
H.3.2.2.5	Croton-oil ear edema in rats and mice	757
H.3.2.2.6	Paw edema	759
H.3.2.2.7	Pleurisy test	762
H.3.2.2.8	Granuloma pouch technique	764
H.3.2.2.9	Urate-induced synovitis	765
H.3.2.3	Methods for testing the proliferative phase (granuloma formation)	767
H.3.2.3.1	Cotton wool granuloma	767
H.3.2.3.2	Sponge implantation technique	768
H.3.2.3.3	Glass rod granuloma	769
H.3.3	Side effects of anti-inflammatory compounds	769
H.3.3.1	General considerations	769
H.3.3.2	Ulcerogenic effect in rats	770
H.3.3.3	Measurement of gastric mucosal damage by intragastric inulin ...	771
H.3.3.4	Determination of blood loss	771
H.4	Antipyretic activity	772
H.4.0.1	General considerations	772
H.4.0.2	Antipyretic testing in rats	772
H.4.0.3	Antipyretic testing in rabbits	773

Chapter I

Antiarthrotic and immunomodulatory activity

I.1	Anti-arthrotic activity	775
I.1.0.1	General considerations	775
I.1.1	<i>In vitro</i> methods for anti-osteoarthritic activity	776
I.1.1.1	General considerations	776
I.1.1.2	Modulation of cellular proteoglycan metabolism	777
I.1.1.3	Cellular chondrocytic chondrolysis	779
I.1.1.4	Cartilage explant chondrolysis	781
I.1.2	<i>In vivo</i> methods for anti-osteoarthritic activity	782
I.1.2.1	General considerations	782
I.1.2.2	Canine anterior cruciate ligament (ACL) transection model	784
I.1.2.3	Chymopapain-induced cartilage degeneration in the rabbit	786
I.1.2.4	Spontaneous OA model in STR/1N mice	787

I.2	Methods for testing immunological factors	788
I.2.1	<i>In vitro</i> methods	788
I.2.1.1	Inhibition of histamine release from mast cells	788
I.2.1.2	Mitogen induced lymphocyte proliferation	790
I.2.1.3	Inhibition of T cell proliferation	791
I.2.1.4	Chemiluminescence in macrophages	792
I.2.1.5	PFC (plaque forming colony) test <i>in vitro</i>	793
I.2.1.6	Inhibition of dihydro-orotate dehydrogenase	794
I.2.2	<i>In vivo</i> methods for testing immunological factors	795
I.2.2.1	Spontaneous autoimmune diseases in animals	795
I.2.2.2	Acute systemic anaphylaxis in rats	797
I.2.2.3	Anti-anaphylactic activity (Schultz-Dale reaction)	798
I.2.2.4	Passive cutaneous anaphylaxis	799
I.2.2.5	Arthus type immediate hypersensitivity	800
I.2.2.6	Delayed type hypersensitivity	800
I.2.2.7	Reversed passive Arthus reaction	801
I.2.2.8	Adjuvant arthritis in rats	802
I.2.2.9	Collagen type II induced arthritis in rats	806
I.2.2.10	Proteoglycan-induced progressive polyarthritis in mice	807
I.2.2.11	Experimental autoimmune thyroiditis	808
I.2.2.12	Coxsackievirus B3-induced myocarditis	809
I.2.2.13	Porcine cardiac myosin-induced autoimmune myocarditis in rats	810
I.2.2.14	Experimental allergic encephalomyelitis	811
I.2.2.15	Acute graft versus host disease (GVHD) in rats	813
I.2.2.16	Influence on SLE-like disorder in MRL/lpr mice	814
I.2.2.17	Prevention of experimentally induced myasthenia gravis in rats	816
I.2.2.18	Glomerulonephritis induced by ant basement membrane antibody in rats	818
I.2.2.19	Auto-immune uveitis in rats	820
I.2.2.20	Inhibition of allogenic transplant rejection	820
Chapter J		
Activity on the gastrointestinal tract		825
J.1	Salivary glands	827
J.1.0.1	Measurement of salivation	827
J.2	Esophagus	828
J.2.0.1	Tunica muscularis mucosae of esophagus <i>in vitro</i>	828
J.2.0.2	Esophageal sphincter <i>in vivo</i>	832
J.2.0.3	Permanent fistula of the esophagus in the dog	833
J.3	Gastric function	833
J.3.1	Acid secretion	833
J.3.1.1	Acid secretion in perfused rat stomach (Gosh and Schild rat)	833
J.3.1.2	Isolated rat stomach	835
J.3.1.3	Chronic gastric fistula in rats	835
J.3.1.4	Chronic gastric fistula in dogs	837
J.3.1.5	Heidenhain pouch in dogs	838
J.3.1.6	Gastrin activity	840
J.3.1.7	Receptor binding for gastrin	841
J.3.1.8	Gastrin releasing peptide/bombesin/neuromedin	842
J.3.1.9	Bombesin receptor binding	844
J.3.1.10	Evaluation of bombesin receptor antagonists as anti-cancer drugs	845

J.3.2	Mucus secretion	848
J.3.2.1	Isolated gastric mucosal preparation	848
J.3.2.2	Primary culture of rat gastric epithelial cells	849
J.3.3	Gastric motility	850
J.3.3.1	Measurement of intragastric pressure in rats	850
J.3.3.2	Isolated smooth muscle preparation of guinea pig stomach	851
J.3.4	Absorption	852
J.3.4.1	Measurement of gastric absorption of drugs in rats	852
J.3.5	Antacid activity	853
J.3.5.1	Evaluation of antacids	853
J.3.6	Inhibition of HCl secretion	854
J.3.6.1	Anticholinergic activity	854
J.3.6.1.1	General considerations	854
J.3.6.1.2	Acetylcholine receptor binding	854
J.3.6.2	H ₂ -antagonism	857
J.3.6.2.1	General considerations	857
J.3.6.2.2	Histamine H ₂ -receptor binding	858
J.3.6.2.3	H ₂ -antagonism in isolated guinea pig right atria	859
J.3.6.2.4	H ₂ -antagonism in isolated rat uterus	859
J.3.6.2.5	Activity at histamine H ₁ - and H ₂ -receptors <i>in vivo</i>	860
J.3.6.2.6	Inhibition of histamine stimulated adenylate cyclase from gastric mucosa	861
J.3.6.3	H ⁺ /K ⁺ -ATPase (proton pump) inhibition	861
J.3.6.3.1	General considerations	861
J.3.6.3.2	H ⁺ /K ⁺ -ATPase inhibition in membrane vesicles of stomach mucosa	862
J.3.6.3.3	Effect of H ⁺ /K ⁺ -ATPase inhibitors on serum gastrin levels	863
J.3.6.3.4	(¹⁴ C)-aminopyrine uptake and oxygen consumption in isolated rabbit gastric glands	864
J.3.6.3.5	Gastric mucosal blood flow	866
J.3.7	Anti-ulcer activity	867
J.3.7.1	Pylorus ligation in rats (SHAY rat)	867
J.3.7.2	Stress ulcer through immobilization stress	868
J.3.7.3	Stress ulcers by cold water immersion	869
J.3.7.4	Indomethacin induced ulcers in rats	869
J.3.7.5	Ethanol induced mucosal damage in rats (cytoprotective activity)	870
J.3.7.6	Subacute gastric ulcer in rats	871
J.3.7.7	Gastric ischemia-reperfusion injury in rats	872
J.4	Intestinal functions	873
J.4.1	Intestinal secretion	873
J.4.1.1	Laxative activity in rats	873
J.4.1.2	Enteropooling test	874
J.4.1.3	Inhibition of chloride secretion in rabbit colon	874
J.4.2	Antidiarrhea effect	875
J.4.2.1	Castor oil induced diarrhea	875
J.4.2.2	Antidiarrheal effect in cecectomized rats	876
J.4.2.3	Evaluation of antidiarrheal effect in cold-restrained rats	877
J.4.3	Gut motility	878
J.4.3.1	Isolated ileum (MAGNUS technique)	878
J.4.3.2	Cascade superfusion technique	881
J.4.3.3	<i>In vivo</i> evaluation of spasmolytic activity in rats	882
J.4.3.4	Colon motility in anesthetized rats	882
J.4.3.5	Continuous recording of electrical and mechanical activity in the gut of the conscious rat	883
J.4.3.6	Propulsive gut motility in mice	884

J.4.3.7	Nerve-jejunum preparation of the rabbit	885
J.4.3.8	Motility of gastrointestinal tract in dogs	886
J.4.3.9	Thiry-Vella fistula	886
J.4.3.10	Continuous recording of mechanical and electrical activity in the intestine of conscious dogs	888
J.4.4	Absorption	890
J.4.4.1	Everted sac technique	890
J.4.4.2	Stomach emptying and intestinal absorption in rats	891
J.4.4.3	Intestinal drug absorption	893
J.4.5	Duodenal ulcer formation	894
J.4.5.1	Cysteamine-induced duodenal ulcers in rats	894
J.4.6	Models of inflammatory gut disease	895
J.4.6.1	Experimental ileitis	895
J.4.6.2	Experimental colitis	896
J.5	Emetic and anti-emetic activity	901
J.5.0.1	Assessment of emetic and anti-emetic activity in dogs	901
J.5.0.2	Anti-emetic activity in ferrets	902
J.5.0.3	Assessment of emetic and anti-emetic activity in pigeons	904
J.5.0.4	Activity against motion-induced emesis	904
J.5.0.5	Foot tapping in gerbils	905
J.6	Gall bladder functions	906
J.6.1	Bile secretion	906
J.6.1.1	Cholagogic activity in mice	906
J.6.1.2	Choleretic activity in rats	906
J.6.1.3	Chronic bile fistula in rats	907
J.6.1.4	Chronic bile fistula in dogs	909
J.6.2	Gall bladder motility	910
J.6.2.1	Activity on isolated gall-bladder strips from guinea pigs	910
J.6.2.2	Gallbladder motility in dogs	910
J.6.2.3	Cholecystokinin activity (isolated gallbladder or intestine)	911
J.6.3	Sphincter Oddi function	911
J.6.3.1	Relaxation of sphincter of Oddi <i>in vitro</i>	912
J.6.3.2	Function of sphincter of Oddi <i>in vivo</i>	913
J.7	Pancreatic function	914
J.7.0.1	Acute pancreatic fistula in rats	914
J.7.0.2	Exocrine secretion of isolated pancreas	915
J.7.0.3	Chronic pancreatic fistula in rats	916
J.7.0.4	Acute pancreatic fistula in dogs	917
J.7.0.5	Chronic pancreatic fistula in dogs	918
J.7.0.6	Somatostatin activity	919
J.7.0.7	Receptor binding for somatostatin	921
J.7.0.8	Secretin activity	924
J.7.0.9	Receptor binding for secretin	924
J.7.0.10	Cholecystokinin activity (isolated rat pancreatic acini)	926
J.7.0.11	Receptor binding of cholecystokinin	927
J.7.0.12	Acute experimental pancreatitis	931
J.7.0.13	Taurocholate-induced pancreatitis in the rat	933
J.7.0.14	Chronic pancreatitis	934
J.8	Liver function	936
J.8.1	Hepatocellular function	936
J.8.1.1	Hepatitis in Long Evans Cinnamon rats	936

J.8.1.2	Temporary hepatic ischemia	937
J.8.1.3	Model for direct transhepatic studies in dogs	938
J.8.2	Liver cirrhosis and necrosis	938
J.7.2.1	General considerations	938
J.8.2.2	Inhibition of proline hydroxylation	939
J.8.2.3	Influence on collagen synthesis in human skin fibroblasts	940
J.8.2.4	Influence on collagen synthesis in chicken calvaria	941
J.8.2.5	Allyl alcohol induced liver necrosis in rats	941
J.8.2.6	Carbontetrachloride induced liver fibrosis in rats	942
J.8.2.7	Bile duct ligation induced liver fibrosis in rats	943
J.8.2.8	Galactosamine induced liver necrosis	944
J.9	Eviscerated animals	945
J.9.1	Evisceration in rats	945
J.9.2	Evisceration in rabbits	945

Chapter K

Antidiabetic activity	947
------------------------------------	------------

K.1	Methods to induce experimental diabetes mellitus	948
K.1.0.1	Pancreatectomy in dogs	948
K.1.0.2	Alloxan induced diabetes	950
K.1.0.3	Streptozotocin induced diabetes	951
K.1.0.4	Other diabetogenic compounds	952
K.1.0.5	Hormone induced diabetes	952
K.1.0.6	Insulin deficiency due to insulin antibodies	953
K.1.0.7	Virus induced diabetes	953
K.2	Genetically diabetic animals	954
K.2.0.1	General considerations	954
K.2.0.2	Spontaneously diabetic rats	954
K.2.0.3	Spontaneously diabetic mice	958
K.2.0.4	Chinese hamster	961
K.2.0.5	Other species with inherited diabetic symptoms	962
K.2.0.6	Transgenic animals	964
K.3	Assays of insulin and of insulin-like activity	965
K.3.1	Hypoglycemic effects	965
K.3.1.1	Blood sugar lowering effect in rabbits	965
K.3.1.2	Hypoglycemic seizures in mice	967
K.3.1.4	Blood sugar determinations in mice	968
K.3.2	Insulin target cells/tissues of rats	968
K.3.2.1	Epididymal fat pad of rats	968
K.3.2.2	Fat cells isolated by digestion with collagenase	969
K.3.2.3	Primary culture of rat adipocytes	969
K.3.2.4	3T3 Adipocytes	969
K.3.2.5	Lipogenesis assay	970
K.3.2.6	Assays of glucose transport	971
K.3.2.7	Adipocyte plasma membranes	972
K.3.2.8	Effect on glucose transporter translocation	974
K.3.2.9	Influence on further metabolic functions	977
K.3.2.10	Insulin signaling cascade	980
K.3.2.11	Insulin signaling in the liver	983
K.3.2.12	Insulin receptor substrate	986

K.3.2.13	Effect of insulin on glycosyl-phosphatidylinositol-specific phospholipase C	991
K.3.2.14	Preparation of caveolae and detergent-insoluble glycolipid-enriched raft domains (DIGs)	994
K.3.3	Isolated diaphragm of rats or mice	999
K.3.3.1	Glycogen synthesis	999
K.3.3.2	Glucose transport	999
K.3.3.3	Glycogen synthase	1000
K.3.4	Binding assays	1001
K.3.4.1	Immunoassay	1001
K.3.4.2	Insulin receptor binding	1002
K.4	Assays of other glucose regulating peptide hormones	1005
K.4.0.1	Bioassay of glucagon	1005
K.4.0.2	Receptor binding and <i>in vitro</i> activity of glucagon	1006
K.4.0.3	Glucagon-like peptide I	1007
K.4.0.4	Insulin-like growth factors	1010
K.4.0.5	Amylin	1013
K.4.0.5.1	General considerations	1013
K.4.0.5.2	Receptor binding of amylin	1015
K.5	Blood glucose lowering activity of antidiabetic drugs	1016
K.5.0.1	Blood glucose lowering activity in rabbits	1016
K.5.0.2	Blood glucose lowering activity in rats	1016
K.5.0.3	Blood glucose lowering activity in dogs	1017
K.5.0.4	Euglycemic clamp technique	1018
K.5.0.5	Effects of insulin sensitizer drugs	1020
K.5.0.6	Effects of thiazolidinediones on peroxisome proliferator-activated receptor- γ	1022
K.6	Activity in isolated organs, cells, and membranes	1024
K.6.1	Effects on pancreas	1024
K.6.1.1	Perfusion of isolated rat pancreas	1024
K.6.1.2	Perfusion of isolated rat pancreatic islets	1025
K.6.1.3	Insulin producing tumor cells	1026
K.6.1.4	Isolation of membranes	1028
K.6.1.5	Receptor binding of sulfonylureas	1028
K.6.1.6	Interaction of sulfonylureas with β -cells	1030
K.6.1.7	Photoaffinity labeling of β -cell membranes	1033
K.6.1.8	$^{86}\text{Rb}^+$ efflux measurements	1034
K.6.1.9	Membrane potential (measurement of the ATP sensitive potassium channel by voltage-clamp technique)	1035
K.6.2	Effects on liver	1036
K.6.2.1	Perfusion of isolated rat liver	1036
K.6.2.2	Isolated hepatocytes	1037
K.6.2.3	Fructose-2,6-bisphosphate production in rat hepatocytes	1038
K.6.3	Effects on muscle	1039
K.6.3.1	Perfused hind limb in rats	1039
K.6.3.2	Isolated diaphragm	1040
K.6.3.3	Activity on isolated muscle cells	1040
K.6.4	Effects on adipose tissue	1042
K.7	Inhibition of polysaccharide degrading enzymes	1042
K.7.0.1	General considerations	1042
K.7.0.2	Inhibition of α -amylase <i>in vitro</i>	1042

K.7.0.3	Inhibition of glucosidase <i>in vitro</i>	1043
K.7.0.4	Evaluation of α -glucosidase inhibitors using the everted sac technique	1043
K.7.0.5	Inhibition of glucose absorption <i>in vivo</i>	1043

K.8	Effect on secondary diabetes symptoms	1044
K.8.1	Inhibition of aldose reductase	1044
K.8.1.1	General considerations	1044
K.8.1.2	Aldose reductase inhibition <i>in vitro</i>	1045
K.8.1.3	Effect on nerve conduction velocity	1046
K.8.1.4	Effect on nerve blood flow (Doppler flux)	1047
K.8.1.5	Electroretinogram in diabetic hyperglycemia and galactosemia	1048
K.8.1.6	Effect on streptozotocin induced cataract	1049
K.8.1.7	Determination of aldose reductase in rat lens	1049
K.8.1.8	Effect on naphthalene induced cataract	1051

Chapter L

Anti-obesity activity	1053
------------------------------------	------

L.1	Methods to induce experimental obesity	1053
L.1.0.1	General considerations	1053
L.1.0.2	Food induced obesity	1054
L.1.0.3	Hypothalamic obesity	1055
L.1.0.4	Goldthioglucose-induced obesity	1056
L.1.0.5	Monosodium glutamate-induced obesity	1057

L.2	Genetically obese animals	1058
L.2.0.1	General considerations	1058
L.2.0.2	Spontaneously obese rats	1058
L.2.0.3	Spontaneously obese mice	1061
L.2.0.4	Transgenic animals	1065

L.3	Assays of anti-obesity activity	1065
L.3.1	Anorectic activity	1065
L.3.1.1	Food consumption in rats	1065
L.3.2	Metabolic activity	1068
L.3.2.1	GDP-binding in brown adipose tissue	1068
L.3.2.2	Uncoupling protein and GLUT4 in brown adipose tissue	1069
L.3.2.3	Resting metabolic rate	1072
L.3.2.4	β_3 -adrenoceptor	1074

L.4	Assays of obesity regulating peptide hormones	1075
L.4.0.1	Hormonal regulation of food intake	1075
L.4.1	Leptin	1078
L.4.1.1	General considerations on the obese gene product leptin	1078
L.4.1.2	Determination of leptin mRNA level in adipose tissue	1079
L.4.1.3	Determination of plasma leptin	1080
L.4.2	Neuropeptide Y	1081
L.4.2.1	General considerations on neuropeptide Y and related peptides .	1081
L.4.2.2	Receptor assay of neuropeptide Y	1083
L.4.3	Orexin	1085
L.4.3.1	General considerations on orexin	1085
L.4.3.2	Receptor assay of orexin	1086
L.4.3.3	Radioimmunoassay for orexin	1087

L.4.4	Galanin	1087
L.4.4.1	General considerations on galanin	1087
L.4.4.2	Receptor assay of galanin	1090
L.4.5	Adipsin	1091
L.4.5.1	General considerations on adipsin	1091
L.4.5.2	Adipsin expression in mice	1092

Chapter M

Anti-atherosclerotic activity 1095

M.1	Induction of experimental atherosclerosis	1095
M.1.0.1	General considerations	1095
M.1.0.2	Cholesterol-diet induced atherosclerosis in rabbits and other species ..	1096
M.1.0.3	Hereditary hypercholesterolemia in rats	1099
M.1.0.4	Hereditary hyperlipemia in rabbits	1099
M.1.0.5	Transgenic animals	1099
M.1.0.6	Evaluation of endothelial function in rabbits with atherosclerosis ..	1100
M.1.0.7	Intimal reactions after endothelial injury	1101
M.2	Influence on lipid metabolism	1102
M.2.0.1	General considerations	1102
M.2.0.2	Hypolipidemic activity in rats	1103
M.2.0.3	Hypolipidemic activity in Syrian hamsters	1105
M.2.0.4	Triton-induced hyperlipidemia	1106
M.2.0.5	Fructose induced hypertriglyceridemia in rats	1107
M.2.0.6	Intravenous lipid tolerance test in rats	1107
M.2.0.7	Influence on lipoprotein-lipase activity	1108
M.2.0.8	Influence on several steps of cholesterol absorption and formation ..	1108
M.3	Inhibition of cholesterol biosynthesis	1111
M.3.1	General considerations on cholesterol biosynthesis	1111
M.3.2	Determination of HMG-CoA-reductase inhibitory activity	1113
M.3.2.1	General considerations on HMG-CoA reductase	1113
M.3.2.2	Inhibition of the isolated enzyme HMG-CoA-reductase <i>in vitro</i> ...	1114
M.3.2.3	Inhibition of the incorporation of ¹⁴ C sodium acetate into cholesterol in isolated liver cells	1115
M.3.2.4	<i>Ex vivo</i> inhibition of cholesterol biosynthesis in isolated rat liver slices ..	1116
M.3.2.5	Effect of HMG-CoA -reductase inhibitors <i>in vivo</i>	1117
M.4	Inhibition of cholesterol absorption	1118
M.4.1	Inhibition of ACAT (Acyl coenzyme A:cholesterol acyltransferase) ..	1118
M.4.1.1	General considerations	1118
M.4.1.2	<i>In vitro</i> ACAT inhibitory activity	1119
M.4.1.3	<i>In vivo</i> tests for ACAT inhibitory activity	1120
M.4.1.4	Lymph fistula model for cholesterol absorption	1121
M.5	Interruption of bile acid recirculation	1122
M.5.0.1	Cholestyramine binding	1122
M.6	Inhibition of lipid oxidation	1123
M.6.0.1	General considerations	1123
M.6.0.2	Inhibition of lipid peroxidation of isolated plasma low density lipoproteins	1123
M.6.0.3	Internalization of labeled LDL into HepG2 cells	1124

Chapter N		
Endocrinology		1127
N.1	Endocrine survey	1130
N.2	Adrenal steroid hormones	1131
N.2.0.1	Adrenalectomy in rats	1131
N.2.1	Glucocorticoid activity	1131
N.2.1.1	<i>In vitro</i> methods for glucocorticoid hormones	1131
N.2.1.1.1	Corticoid receptor binding	1131
N.2.1.1.2	Transactivation assay for glucocorticoids	1135
N.2.1.1.3	Induction of tyrosine aminotransferase in hepatoma cells	1135
N.2.1.1.4	Effect on T-lymphocytes	1135
N.2.1.1.5	Inhibition of cartilage degradation	1137
N.2.1.2	<i>In vivo</i> methods for glucocorticoid hormones	1137
N.2.1.2.1	General considerations	1137
N.2.1.2.2	Adrenal and thymus involution	1138
N.2.1.2.3	Eosinopenia test in adrenalectomized mice	1138
N.2.1.2.4	Liver glycogen test in rats	1139
N.2.1.2.5	Anti-inflammatory tests	1139
N.2.1.3	Influence of steroids on mechanical properties of connective tissue	1140
N.2.1.3.1	Breaking strength of bones	1140
N.2.1.3.2	Tensile strength of femoral epiphyseal cartilage in rats	1141
N.2.1.3.3	Tensile strength of tail tendons in rats	1141
N.2.1.3.4	Tensile strength of skin strips in rats	1142
N.2.1.4	Topical activity of glucocorticosteroids	1143
N.2.1.4.1	Skin thickness and tensile strength	1143
N.2.1.4.2	Assay of topical glucocorticoid activity in transgenic mice	1145
N.2.1.4.3	Effect on epidermal DNA synthesis	1146
N.2.1.4.4	Induction of drug metabolizing enzymes	1146
N.2.1.4.5	Cornea inflammation in rabbits	1147
N.2.1.4.6	Endotoxin-induced uveitis in rats	1148
N.2.1.5	Anti-glucocorticoid activity	1148
N.2.1.5.1	Adrenal and thymus involution	1148
N.2.2	Mineralocorticoid activity	1149
N.2.2.1	<i>In vivo</i> methods	1149
N.2.2.1.1	General considerations	1149
N.2.2.1.2	Electrolyte excretion	1149
N.2.2.2	<i>In vitro</i> methods	1150
N.2.2.2.1	Mineralocorticoid receptor binding	1150
N.2.2.2.2	Transactivation assay for mineralocorticoids	1151
N.2.2.3	Antimineralocorticoid activity	1153
N.2.2.3.1	Electrolyte excretion	1153
N.3	Ovarian hormones	1154
N.3.0.1	Castration of female rats	1154
N.3.1	Estrogens	1154
N.3.1.1	<i>In vitro</i> methods	1154
N.3.1.1.1	Estrogen receptor binding	1154
N.3.1.1.2	Transactivation assay for estrogens	1156
N.3.1.1.3	Estrogen dependent cell proliferation	1158
N.3.1.2	<i>In vivo</i> methods	1159
N.3.1.2.1	Vaginal cornification	1159
N.3.1.2.2	Uterus weight	1159

N.3.1.2.3	Chick oviduct method	1160
N.3.1.3	Anti-estrogenic activity	1161
N.3.1.3.1	Antagonism of uterus weight increase due to estrogen treatment ...	1161
N.3.1.3.2	Aromatase inhibition	1161
N.3.1.3.3	Anti-estrogenic effect on MCF-7 breast cancer cells	1162
N.3.2	Progestational activity	1163
N.3.2.1	<i>In vitro</i> methods	1163
N.3.2.1.1	Gestagen receptor binding	1163
N.3.2.1.2	Transactivation assay for gestagens	1165
N.3.2.1.3	Alkaline phosphatase assay	1167
N.3.2.2	<i>In vivo</i> methods	1167
N.3.2.2.1	Clauberg (McPhail) test in rabbits	1167
N.3.2.2.2	Endometrial carbonic anhydrase	1168
N.3.2.2.3	Deciduoma formation	1169
N.3.2.2.4	Pregnancy maintenance	1169
N.3.2.3	Anti-progestational activity	1170
N.3.2.3.1	Progesterone antagonism	1170
N.3.2.3.2	Luteolytic effect of prostaglandins	1171
N.4	Testicular steroid hormones	1172
N.4.0.1	Castration of male rats	1172
N.4.0.2	Caponizing of cockerels	1172
N.4.1	Androgenic and anabolic activity	1173
N.4.1.1	<i>In vitro</i> methods	1173
N.4.1.1.1	Androgen receptor binding	1173
N.4.1.1.2	Transactivation assay for androgens	1175
N.4.1.2	<i>In vivo</i> methods	1176
N.4.1.2.1	Chicken comb method	1176
N.4.1.2.2	Weight of ventral prostate, seminal vesicles and musculus levator ani	1177
N.4.1.2.3	Nitrogen retention	1177
N.4.2	Anti-androgenic activity	1178
N.4.2.0.1	General considerations	1178
N.4.2.1	<i>In vitro</i> methods	1178
N.4.2.1.1	Inhibition of 5 α -reductase	1178
N.4.2.2	<i>In vivo</i> methods	1180
N.4.2.2.1	Chick comb method	1180
N.4.2.2.2	Antagonism of the effect of testosterone on weight of ventral prostate, seminal vesicles and musculus levator ani	1181
N.4.2.2.3	Anti-androgenic activity in female rats	1182
N.4.2.2.4	Intra-uterine feminizing/virilizing effect	1182
N.4.2.2.5	Anti-androgenic activity on sebaceous glands	1183
N.4.2.2.6	Anti-androgenic activity in the hamster flank organ	1183
N.4.2.2.7	Effect of 5 α -reductase inhibitors on plasma and tissue steroid levels	1183
N.5	Thyroid hormones	1184
N.5.0.1	General considerations	1184
N.5.0.2	Thyroidectomy	1185
N.5.1	<i>In vivo</i> tests for thyroid hormones	1186
N.5.1.1	Oxygen consumption	1186
N.5.1.2	Inhibition of iodine release	1187
N.5.1.3	Anti-goitrogenic activity	1187
N.5.1.4	Tensile strength of connective tissue in rats, modified for thyroid hormones	1188

N.5.2	Antithyroid drugs	1188
N.5.2.1	General considerations	1188
N.5.2.2	Inhibition of iodine uptake into the thyroid of rats	1189
N.5.2.3	Antithyroidal effect on oxygen consumption in iodine treated mice ..	1189
N.5.3	Calcitonin	1190
N.5.3.1	General considerations	1190
N.5.3.2	Decrease of serum calcium in rats	1190
N.5.3.3	Effect of calcitonin on osteoclasts <i>in vitro</i>	1191
N.5.3.4	Receptor binding and cAMP accumulation in isolated cells	1192
N.6	Parathyroid hormone	1194
N.6.0.1	General considerations	1194
N.6.0.2	Receptor binding assay for PTH	1195
N.6.0.3	PTH assay by serum calcium increase	1196
N.6.0.4	Serum phosphate decrease after PTH	1197
N.6.0.5	cAMP release in isolated perfused rat femur	1197
N.6.0.6	Renal and metatarsal cytochemical bioassay	1198
N.6.0.7	cAMP accumulation in cultured cells	1199
N.6.0.8	Anabolic activity in ovariectomized, osteopenic rats	1200
N.7	Anterior pituitary hormones	1201
N.7.0.1	Hypophysectomy in rats	1201
N.7.1	Gonadotropins	1202
N.7.1.0.1	General considerations	1202
N.7.1.1	Follicle-stimulating hormone (FSH)	1203
N.7.1.1.1	Ovarian weight in HCG-primed rats	1203
N.7.1.1.2	[³ H]thymidine uptake in cultured mouse ovaries	1204
N.7.1.1.3	Granulosa cell aromatase assay <i>in vitro</i>	1205
N.7.1.1.4	Sertoli cell aromatase assay <i>in vitro</i>	1206
N.7.1.1.5	Receptor binding assay for FSH	1207
N.7.1.2	Luteinizing hormone (LH) = Interstitial cell stimulating hormone (ICSH)	1208
N.7.1.2.1	Prostate weight in hypophysectomized rats	1209
N.7.1.2.2	Superovulation in immature rats	1209
N.7.1.2.3	Ascorbic acid depletion of ovaries in PMSG/HCG primed rats	1209
N.7.1.2.4	Testosterone production by Leydig cells <i>in vitro</i> induced by LH ...	1210
N.7.1.2.5	Receptor binding assay for LH	1211
N.7.1.3	Other gonadotropins	1212
N.7.1.4	Human chorionic gonadotropin (hCG)	1212
N.7.1.4.1	Corpus luteum formation in immature mice (Aschheim-Zondek test)	1212
N.7.1.4.2	Biological assay of hCG in immature male rats	1212
N.7.1.4.3	Receptor binding assay for hCG	1213
N.7.1.5	Human menopausal gonadotropin (hMG)	1213
N.7.1.5.1	Biological assay of hMG in immature rats	1213
N.7.1.6	Pregnant mares' serum gonadotropin (PMSG)	1214
N.7.1.6.1	Biological assay of PMSG in immature female rats	1214
N.7.1.7	Immunoassays of gonadotropins	1214
N.7.1.8	Gonadotropin inhibition	1214
N.7.1.8.1	General considerations	1214
N.7.1.8.2	Inhibition of gonadotropin secretion in intact animals	1215
N.7.1.8.3	Inhibition of ovulation and luteinization	1215
N.7.1.8.4	Ovary-spleen-transplantation	1216
N.7.1.8.5	Inhibition of fertility	1217
N.7.2	Prolactin	1218

N.7.2.1	General considerations	1218
N.7.2.2	Radioimmunoassay of rat prolactin	1218
N.7.2.3	Pigeon crop method	1218
N.7.2.4	Lactation in rabbits	1219
N.7.3	Growth hormone (GH)	1220
N.7.3.1	General considerations	1220
N.7.3.2	Weight gain in female rats ("growth plateaued rats")	1220
N.7.3.3	Tibia test in hypophysectomized rats	1221
N.7.3.4	³⁵ S uptake	1222
N.7.3.5	Inhibition of glucose uptake in adipocytes <i>in vitro</i>	1222
N.7.3.6	Eluted stain bioassay for human growth hormone	1223
N.7.3.7	Reverse hemolytic plaque assay for growth hormone	1224
N.7.3.8	Determination of growth hormone isoforms by 22-kD GH exclusion assay	1225
N.7.3.9	Steroid regulation of growth hormone receptor and GH-binding protein	1225
N.7.4	Adrenocorticotropin (ACTH)	1227
N.7.4.1	Adrenal ascorbic acid depletion	1227
N.7.4.2	Corticosterone blood levels in dexamethasone blocked rats	1228
N.7.4.3	<i>In vitro</i> corticosteroid release	1229
N.7.4.4	Thymus involution	1230
N.7.4.5	Receptor binding assay for ACTH	1231
N.7.5	Thyrotropin (TSH)	1232
N.7.5.1	General considerations	1232
N.7.5.2	Thyroid histology	1232
N.7.5.3	Iodine uptake	1233
N.7.5.4	TSH bioassay based on cAMP accumulation in CHO cells	1233
N.7.6	Hormones related to TSH	1234
N.7.6.1	General considerations	1234
N.7.6.2	Assay of exophthalmus-producing substance (EPS) in fishes	1234
N.7.6.3	Assay of long acting thyroid stimulating factor (LATS) in mice	1235
N.8	Posterior pituitary hormones	1236
N.8.0.1	General considerations	1236
N.8.1	Oxytocin	1237
N.8.1.1	Isolated uterus	1237
N.8.1.2	Chicken blood pressure	1238
N.8.1.3	Milk ejection in the lactating rabbit or rat	1239
N.8.1.4	Oxytocin receptor determination	1240
N.8.2	Vasopressin	1241
N.8.2.1	Hereditary vasopressin deficiency in rats (Brattleboro strain)	1241
N.8.2.2	Vasopressor activity	1242
N.8.2.3	Antidiuretic activity in the conscious rat	1243
N.8.2.4	Antidiuretic activity in the rat in ethanol anesthesia	1243
N.8.2.5	Spasmogenic activity of vasopressin in the isolated guinea pig ileum .	1244
N.8.2.6	Vasopressin receptor determination	1244
N.9	Hypothalamic hormones	1247
N.9.1	Thyrotropin releasing hormone (TRH)	1247
N.9.1.1	General considerations	1247
N.9.1.2	TRH receptor binding assays	1247
N.9.1.3	Release of ¹³¹ I from thyroid glands of mice	1248
N.9.1.4	Release of TSH from rat anterior pituitary glands <i>in vitro</i>	1249
N.9.2	Luteinizing hormone releasing hormone (LH-RH)	1250
N.9.2.1	General considerations	1250

N.9.2.2	LH-RH receptor assays	1251
N.9.2.3	LH release in the ovariectomized estrogen-progesterone-blocked rat ..	1253
N.9.2.4	Gonadotropin release from anterior pituitary cells	1254
N.9.2.5	Radioimmunoassay of rat-LH	1255
N.9.2.6	Radioimmunoassay of rat-FSH	1256
N.9.2.7	Measurement of ascorbic acid depletion in ovaries of pseudo-pregnant rats	1256
N.9.2.8	Progesterone production in pseudopregnant rats	1257
N.9.2.9	Induction of ovulation in rabbits	1257
N.9.2.10	Induction of superovulation in immature rats	1258
N.9.2.11	Inhibition of experimentally induced endometriosis	1258
N.9.3	LH-RH antagonistic activity	1259
N.9.3.1	Testosterone suppression in rats	1259
N.9.3.2	Antioviulatory activity in rats	1260
N.9.3.3	Effect of repeated administration of LH-RH antagonists in rats	1261
N.9.3.4	Inhibition of gonadotropin release from anterior pituitary cultures ...	1262
N.9.3.5	Anti-tumor affect of LH-RH antagonists	1262
N.9.4	Corticotropin releasing hormone (CRH)	1263
N.9.4.1	General considerations	1263
N.9.4.2	<i>In vitro</i> assay for CRH activity	1265
N.9.4.3	<i>In vivo</i> bioassay of CRH activity	1266
N.9.4.4	Collection of hypophyseal portal blood in rats	1267
N.9.4.5	CRH receptor determination	1268
N.9.5	Growth hormone releasing hormone (GH-RH)	1270
N.9.5.1	Radioreceptor assay of growth hormone-releasing hormone	1270
N.9.5.2	Growth hormone release from rat pituitaries <i>in vitro</i>	1272
N.9.5.3	GH-RH bioassay by growth hormone release in rats	1274
N.10	Other peptide hormones	1274
N.10.1	Melanophore stimulating hormone	1274
N.10.1.1	Skin darkening in whole amphibia	1274
N.10.1.2	Assay in isolated amphibian skin	1275
N.10.1.3	Binding to the melanocortin receptor	1276
N.10.2	Relaxin	1278
N.10.2.1	General considerations	1278
N.10.2.2	Relaxin bioassay by pubic symphysis method in guinea pigs	1279
N.10.2.3	Relaxin bioassay in mice	1280
N.10.2.4	Inhibition of uterine motility	1280
N.10.2.5	Relaxin assay by interstitial collagenase activity in cultured uterine cervical cells	1281
N.10.2.6	Relaxin receptor binding	1282
N.10.3	Calcitonin gene-related peptide	1283
N.10.3.1	General considerations	1283
N.10.3.2	Receptor binding of CGRP	1286
N.10.4	Inhibin	1287
N.10.4.1	General considerations	1287
N.10.4.2	<i>In vitro</i> bioassay for inhibin	1288
N.10.5	Activin	1289
N.10.5.1	General considerations	1289
N.10.5.2	<i>In vitro</i> bioassay for activin	1290
N.10.6	Follistatin	1292
N.10.6.1	General considerations	1292
N.10.6.2	Immunoassay for follistatin	1292
N.10.7	Further peptide hormones discussed in chapters related to the respective indications	1294

Chapter O		
Ophthalmologic activity		1295
O.1	Introduction	1295
O.2	Intraocular pressure	1295
O.2.1	Acute measurement of intraocular pressure	1295
O.2.2	Measurement of intraocular pressure by telemetry	1297
O.3	Aqueous humor flow rate	1299
O.4	Experimental glaucoma	1300
O.4.1	Alpha-chymotrypsin induced glaucoma	1300
O.5	Local anesthesia of the cornea	1302
O.6	Experimental cataract formation	1302
O.7	Models of eye inflammation	1303
O.7.1	Allergic conjunctivitis	1303
O.7.2	Corneal inflammation	1304
O.7.3	Auto-immune uveitis in rats	1305
O.7.4	Ocular inflammation induced by paracentesis	1307
O.7.5	Ocular inflammation by lens proteins	1308
O.7.6	Proliferative vitreoretinopathy in rabbits	1308
Chapter P		
Pharmacological models in dermatology		1311
P.1	Skin sensitization testing	1312
P.1.1	Guinea pig maximization assay	1312
P.1.2	Popliteal lymph node hyperplasia assay	1313
P.1.3	Local lymph node assay	1314
P.2	Experimental dermatitis	1314
P.2.1	Spontaneous dermatitis	1315
P.2.1.1	NC/Nga mouse as model for atopic dermatitis	1315
P.2.1.2	Moth-eaten mice	1316
P.2.1.3	Spontaneous erythema in hairless rats	1316
P.2.2	Contact dermatitis	1316
P.2.2.1	Skin reaction in mice	1316
P.2.2.2	Non-immunologic contact urticaria	1318
P.3	Pruritus models	1318
P.3.1	Studies in cpdm/cpdm mice	1318
P.4	Psoriasis models	1320
P.4.1	General considerations	1320
P.4.2	<i>In vitro</i> studies with isolated cells	1320
P.4.2.1	Cultured keratinocytes	1320
P.4.2.2	Effect on T lymphocytes	1321
P.4.3	Psoriasis models in normal animals	1323
P.4.3.1	Mouse tail model for psoriasis	1323
P.4.3.2	Rat ultraviolet ray B photodermatitis model for psoriasis	1324

P.4.4	Psoriatic skin diseases in spontaneous mice mutations	1325
P.4.4.1	Flaky skin (<i>fsn</i>) mouse	1325
P.4.4.2	Asebia (<i>ab/ab</i>) mouse	1327
P.4.5	Psoriasiform skin diseases in genetically modified animals	1327
P.4.6	Xenotransplantation of human psoriatic skin	1330
P.5	Scleroderma models	1331
P.5.1	Scleroderma models in chicken	1331
P.5.2	Scleroderma models in mice	1332
P.6	Pemphigus models	1333
P.6.1	Experimentally induced pemphigus in mice	1333
P.7	Ichthyosis vulgaris models	1334
P.7.1	Experimentally induced ichthyosis in mice	1334
P.8	Xeroderma models	1335
P.8.1	Experimentally induced xeroderma in mice	1335
P.9	Acne models	1336
P.9.1	Activity on sebaceous glands of rats	1336
P.9.2	Activity on sebaceous glands of the fuzzy rat	1337
P.9.3	Activity on ear sebaceous glands of Syrian hamsters	1338
P.9.4	Activity on ear sebaceous glands of rabbits	1339
P.9.5	Activity on the hamster flank organ	1340
P.9.6	Activity on the skin of the Rhino mouse	1341
P.9.7	Activity on the skin of the Mexican hairless dog	1343
P.9.8	<i>In vitro</i> sebocyte model	1343
P.10	Skin mycosis	1345
P.10.1	General considerations	1345
P.10.2	<i>In vitro</i> inhibitory activity	1345
P.10.3	<i>In vivo</i> activity in the guinea pig trichophytosis model	1345
P.10.4	Skin penetration	1346
P.11	Biomechanics of skin	1347
P.11.1	General considerations	1347
P.11.2	<i>In vitro</i> (<i>ex vivo</i>) experiments	1348
P.11.2.1	Stress-strain behavior	1348
P.11.2.1.1	Measurement of skin thickness, ultimate load, tensile strength, ultimate strain and modulus of elasticity	1348
P.11.2.1.2	Measurement of mechanical properties at low extension degrees ..	1350
P.11.2.1.3	Step phenomenon	1351
P.11.2.1.4	Anisotropy of skin	1352
P.11.2.1.5	Relaxation phenomenon	1353
P.11.2.1.6	Hysteresis experiment	1354
P.11.2.1.7	Isorheological point	1355
P.11.2.1.8	Creep experiments	1355
P.11.2.1.9	Repeated strain	1356
P.11.2.2	Thermocontraction	1356
P.11.3	<i>In vivo</i> experiments	1358
P.11.3.1	Stress-strain curves <i>in vivo</i>	1358
P.11.3.2	Repeated strain <i>in vivo</i>	1359
P.11.3.3	<i>In vivo</i> recovery after repeated strain	1359
P.11.4	Healing of skin wounds	1360

P.12	Protection against UV light	1362
P.13	Transepidermal water loss (TEWL)	1364
P.14	Influence on hair growth	1365
P.15	Cutaneous microcirculation	1367
P.15.1	General considerations	1367
P.15.2	Laser Doppler velocimetry	1367
P.15.3	Measurement of skin microcirculation by reflectance spectroscopy	1368
 Chapter Q		
	Guidelines for the care and use of laboratory animals	1369
Q.1	Regulations for the care and use of laboratory animals in various countries	1369
Q.2	Techniques of blood collection in laboratory animals	1371
Q.2.1	Introduction	1371
Q.2.2	Aspects of animal welfare	1371
Q.2.3	Total blood volume	1372
Q.2.4	Terminal blood collection	1372
Q.2.5	Non-terminal blood collection	1372
Q.2.5.1	Single blood removal	1372
Q.2.5.2	Multiple blood removal	1372
Q.2.6	Technical aspects of blood removal	1373
Q.2.6.1	Permanent venous cannulation	1373
Q.2.6.2	Retro-orbital bleeding	1373
Q.2.6.3	Cardiac puncture	1374
Q.3	Anesthesia of experimental animals	1375
Q.3.1	Introduction	1375
Q.3.2	Local anesthesia	1375
Q.3.3	General anesthesia	1375
Q.3.3.1	Preparation	1375
Q.3.3.2	Premedication	1375
Q.3.3.2.1	Hydration and base excess	1375
Q.3.3.2.2	Atropine	1376
Q.3.3.2.3	Sedation and pain elimination	1376
Q.3.3.3	Course of anesthesia	1376
Q.3.3.4	Routes of general anesthesia	1377
Q.3.3.4.1	Injection	1377
Q.3.3.4.2	Inhalation	1377
Q.3.3.4.3	Inhalation compounds	1378
Q.3.3.5	Termination of anesthesia	1378
Q.3.4	Postoperative analgesia	1380
Q.4	Euthanasia of experimental animals	1380
Q.4.1	Introduction	1380
Q.4.2	Euthanasia	1380
Q.4.2.1	Physical methods recommended for euthanasia of laboratory animals	1381
Q.4.2.2	Chemical agents recommended for euthanasia of laboratory animals	1381

Q.4.2.3	Methods and agents not to be used for euthanasia of laboratory animals	1382
Q.4.2.4	Recommended methods for euthanasia for specific animal species	1382
Index		1385